Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 60
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Gray matter volume abnormalities and the association with the trajectory of symptoms and functioning in individuals at clinical high Rrisk of Psychosis

  • Si, Shuqing|||0009-0006-6095-254X
  • See, Cheryl R. Z.|||0000-0003-2135-5495
  • Cowling, Emily P.|||0000-0002-0543-4516
  • Tognin, Stefania|||0000-0002-1983-9135
  • Modinos, Gemma|||0000-0002-7870-066X
  • Haan, Lieuwe de, 1960-|||0000-0002-3820-7926
  • Gaag, Mark van der, 1953-|||0000-0002-3525-6415
  • Nelson, Barnaby|||0000-0002-6263-2332
  • Pantelis, Christos|||0000-0002-9565-0238
  • Riecher-Rössler, Anita|||0000-0001-6361-8789
  • Bressan, Rodrigo Affonseca|||0000-0002-0868-4449
  • Barrantes Vidal, Neus|||0000-0002-8671-1238
  • Krebs, Marie Odile|||0000-0002-4715-9890
  • Glenthøj, Birte|||0000-0003-3056-7262
  • Ruhrmann, Stephan|||0000-0002-6022-2364
  • Sachs, Gabriele|||0000-0002-8359-9877
  • Rutten, Bart P. F.|||0000-0002-9834-6346
  • Os, Jim Van|||0000-0002-7245-1586
  • Barker, Gareth John|||0000-0002-5214-7421
  • James, Anthony|||0000-0002-2742-8328
  • Valmaggia, Lucia|||0000-0001-6099-8464
  • McGuire, Philip|||0000-0003-4381-0532
  • Kempton, Matthew|||0000-0003-3541-9947
Background Brain volume alterations in those at clinical high risk (CHR) of psychosis have been reported in many studies. However, the association between these alterations and the longitudinal trajectory of changes in symptoms and functioning remains unexplored. Study Design T1-weighted magnetic resonance imaging (MRI) scans were acquired from 226 CHR and 65 healthy controls (HC) recruited from the EU-GEI high-risk study. Five a priori regions of interest were examined and segmented using FreeSurfer: total gray matter (GM) volume, anterior cingulate cortex (ACC), hippocampus, fusiform gyri, and insula. Brain volumes in the CHR and HC groups were compared at baseline. In the CHR group, linear mixed models were used to investigate the association between baseline brain volume and longitudinal changes in positive symptoms, negative symptoms, and functioning over a 2-year follow-up period. We also compared CHR participants who later transitioned to psychosis (CHR-T, n = 48) and those who did not (CHR-NT, n = 178) in terms of their trajectory of symptoms and functioning. Study Results Compared with HC, CHR participants had lower total GM and fusiform volume at baseline. Lower total GM and hippocampus volume at baseline were associated with higher levels of positive symptoms at baseline and follow-up in CHR individuals, and lower baseline hippocampus volume also predicted future transition. CHR-T and CHR-NT individuals demonstrated distinct symptoms and functioning trajectories over time. Conclusion Our findings suggest that CHR individuals show baseline differences in brain structure compared to HC, which may also predict changes in positive symptoms over the subsequent 2 years.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The effects of recent stressful life events on outcomes in individuals at clinical high risk for psychosis, results from the longitudinal EU-GEI high-risk study

  • See, Cheryl R. Z.|||0000-0003-2135-5495
  • Si, Shuqing|||0009-0006-6095-254X
  • Cowling, Emily P.|||0000-0002-0543-4516
  • Tognin, Stefania|||0000-0002-1983-9135
  • Modinos, Gemma|||0000-0002-7870-066X
  • Gaag, Mark van der, 1953-|||0000-0002-3525-6415
  • Haan, Lieuwe de, 1960-|||0000-0002-3820-7926
  • Velthorst, Eva|||0000-0002-9240-2909
  • McGorry, Patrick|||0000-0002-3789-6168
  • Nelson, Barnaby|||0000-0002-6263-2332
  • Riecher-Rössler, Anita|||0000-0001-6361-8789
  • Bressan, Rodrigo Affonseca|||0000-0002-0868-4449
  • Barrantes Vidal, Neus|||0000-0002-8671-1238
  • Krebs, Marie Odile|||0000-0002-4715-9890
  • Nordentoft, Merete|||0000-0003-4895-7023
  • Ruhrmann, Stephan|||0000-0002-6022-2364
  • Sachs, Gabriele|||0000-0002-8359-9877
  • Rutten, Bart P. F.|||0000-0002-9834-6346
  • Os, Jim Van|||0000-0002-7245-1586
  • McGuire, Philip|||0000-0003-4381-0532
  • Valmaggia, Lucia|||0000-0001-6099-8464
  • Kempton, Matthew|||0000-0003-3541-9947
Background. Recent stressful life events (SLE) are a risk factor for psychosis, but limited research has explored how SLEs affect individuals at clinical high risk (CHR) for psychosis. The current study investigated the longitudinal effects of SLEs on functioning and symptom severity in CHR individuals, where we hypothesized CHR would report more SLEs than healthy controls (HC), and SLEs would be associated with poorer outcomes. Methods. The study used longitudinal data from the EU-GEI High Risk study. Datafrom 331 CHR participants were analyzed to examine the effects of SLEs on changes in functioning, positive and negative symptoms over a 2-year follow-up. We compared the prevalence of SLEs between CHR and HCs, and between CHR who did (CHR-T) and did not (CHR-NT) transition to psychosis. Results. CHR reported 1.44 more SLEs than HC ( p < 0.001), but there was no difference in SLEs between CHR-T and CHR-NT at baseline. Recent SLEs were associated with poorer functioning and more severe positive and negative symptoms in CHR individuals (all p < 0.01) but did not reveal a significant interaction with time. Conclusions. CHR individuals who had experienced recent SLEs exhibited poorer functioning and more severe symptoms. However, as the interaction between SLEs and time was not significant, this suggests SLEs did not contribute to a worsening of symptoms and functioning over the study period. SLEs could be a key risk factor to becoming CHR for psychosis, however further work is required to inform when early intervention strategies mitigating against the effects of stress are most effective.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Serum immune markers and transition to psychosis in individuals at clinical high risk

  • Mondelli, Valeria|||0000-0001-8690-6839
  • Blackman, Graham|||0000-0001-7025-8670
  • Kempton, Matthew|||0000-0003-3541-9947
  • Pollak, Thomas Arthur Nicholls|||0000-0002-6171-0810
  • Iyegbe, Conrad
  • Valmaggia, Lucia|||0000-0001-6099-8464
  • Amminger, G. Paul|||0000-0001-8969-4595
  • Barrantes Vidal, Neus|||0000-0002-8671-1238
  • Bressan, Rodrigo Affonseca|||0000-0002-0868-4449
  • Gaag, Mark van der, 1953-|||0000-0002-3525-6415
  • Haan, Lieuwe de, 1960-|||0000-0002-3820-7926
  • Krebs, Marie Odile|||0000-0002-4715-9890
  • Nordentoft, Merete|||0000-0003-4895-7023
  • Ruhrmann, Stephan|||0000-0002-6022-2364
  • Riecher-Rössler, Anita|||0000-0001-6361-8789
  • Rutten, Bart P. F.|||0000-0002-9834-6346
  • Sachs, Gabriele|||0000-0002-8359-9877
  • Koutsouleris, Nikolaos|||0000-0001-6825-6262
  • McGuire, Philip|||0000-0003-4381-0532
Individuals at clinical high risk (CHR) for psychosis have been found to have altered cytokine levels, but whether these changes are related to clinical outcomes remains unclear. We addressed this issue by measuring serum levels of 20 immune markers in 325 participants (n = 269 CHR, n = 56 healthy controls) using multiplex immunoassays, and then followed up the CHR sample to determine their clinical outcomes. Among 269 CHR individuals, 50 (18.6 %) developed psychosis by two years. Univariate and machine learning techniques were used to compare levels of inflammatory markers in CHR subjects and healthy controls, and in CHR subjects who had (CHR-t), or had not (CHR-nt) transitioned to psychosis. An ANCOVA identified significant group differences (CHR-t, CHR-nt and controls) and post-hoc tests indicated that VEGF levels and the IL-10/IL-6 ratio were significantly higher in CHR-t than CHR-nt, after adjusting for multiple comparisons. Using a penalised logistic regression classifier, CHR participants were distinguished from controls with an area-under the curve (AUC) of 0.82, with IL-6 and IL-4 levels the most important discriminating features. Transition to psychosis was predicted with an AUC of 0.57, with higher VEGF level and IL-10/IL-6 ratio the most important discriminating features. These data suggest that alterations in the levels of peripheral immune markers are associated with the subsequent onset of psychosis. The association with increased VEGF levels could reflect altered blood-brain-barrier (BBB) permeability, while the link with an elevated IL-10/IL-6 ratio points to an imbalance between anti- and pro-inflammatory cytokines.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

The role of premorbid IQ and age of onset as useful predictors of clinical, functional outcomes, and recovery of individuals with a first episode of psychosis

  • Molina-García, Mariola
  • Fraguas, David
  • Rey-Mejías, Ángel del
  • Mezquida, Gisela
  • Sánchez Torres, Ana María
  • Amoretti, Silvia
  • Lobo, Antonio
  • González Pinto, Ana
  • Andreu-Bernabeu, Álvaro
  • Corripio, Iluminada
  • Vieta, Eduard
  • Baeza, Inmaculada
  • Mané, Anna
  • Cuesta, Manuel J.
  • Serna, Elena de la
  • Payá, Beatriz
  • Zorrilla, Iñaki
  • Arango, Celso
  • Bernardo, Miguel
  • Rapado-Castro, Marta
  • Parellada, Mara
  • PEPs Group
Background: premorbid IQ (pIQ) and age of onset are predictors of clinical severity and long-term functioning after a first episode of psychosis. However, the additive influence of these variables on clinical, functional, and recovery rates outcomes is largely unknown. Methods: we characterized 255 individuals who have experienced a first episode of psychosis in four a priori defined subgroups based on pIQ (low pIQ < 85; average pIQ ≥ 85) and age of onset (early onset < 18 years; adult onset ≥ 18 years). We conducted clinical and functional assessments at baseline and at two-year follow-up. We calculated symptom remission and recovery rates using the Positive and Negative Symptoms of Schizophrenia Schedule (PANSS) and the Global Assessment Functioning (GAF or Children-GAF). We examined clinical and functional changes with pair-wise comparisons and two-way mixed ANOVA. We built hierarchical lineal and logistic regression models to estimate the predictive value of the independent variables over functioning or recovery rates. Results: early-onset patients had more severe positive symptoms and poorer functioning than adult-onset patients. At two-year follow-up, only early-onset with low pIQ and adult-onset with average pIQ subgroups differed consistently, with the former having more negative symptoms (d = 0.59), poorer functioning (d = 0.82), lower remission (61% vs. 81.1%), and clinical recovery (34.1% vs. 62.2%). Conclusions: early-onset individuals with low pIQ may present persistent negative symptoms, lower functioning, and less recovery likelihood at two-year follow-up. Intensive cognitive and functional programs for these individuals merit testing to improve long-term recovery rates in this subgroup., This work was supported by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III, PI02/1248, PI03032, PI05/0678, PI08/0208 PI09/01442, PI11/00325, PI12/1303, PI14/00612, PI15/00723, PI17/009977, PI18/00753 cofinanced by ERDF Funds from the European Commission, 'A way of making Europe', CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2). The CERCA Program/Generalitat de Catalunya And Secretaria d'Universitats i Recerca del Departament d'Economia I Coneixement (2017SGR1355). Departament de Salut de la Generalitat de Catalunya, en la convocatoria corresponent a l'any 2017 de concessió de subvencions del Pla Estratègic de Recerca i Innovació en Salut (PERIS) 2016-2020, modalitat Projectes de recerca orientats a l'atenció primària, amb el codi d'expedient SLT006/17/00345. European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7-HEALTH-2009-2.2.1-3-242114 (Project OPTi-MISE), FP7-HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7-HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz and Fundación Mutua Madrileña.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Opposite cannabis-cognition associations in psychotic patients depending on family history

  • González Pinto, Ana
  • González-Ortega, Itxaso
  • Alberich, Susana
  • Ruiz de Azúa, Sonia
  • Bernardo, Miguel
  • Bioque, Miquel
  • Cabrera, Bibiana
  • Corripio, Iluminada
  • Arango, Celso
  • Lobo, Antonio
  • Sánchez Torres, Ana María
  • Cuesta, Manuel J.
  • PEPs Group
The objective of this study is to investigate cognitive performance in a first-episode psychosis sample, when stratifying the interaction by cannabis use and familial or non-familial psychosis. Hierarchical-regression models were used to analyse this association in a sample of 268 first-episode psychosis patients and 237 controls. We found that cannabis use was associated with worse working memory, regardless of family history. However, cannabis use was clearly associated with worse cognitive performance in patients with no family history of psychosis, in cognitive domains including verbal memory, executive function and global cognitive index, whereas cannabis users with a family history of psychosis performed better in these domains. The main finding of the study is that there is an interaction between cannabis use and a family history of psychosis in the areas of verbal memory, executive function and global cognition: that is, cannabis use is associated with a better performance in patients with a family history of psychosis and a worse performance in those with no family history of psychosis. In order to confirm this hypothesis, future research should explore the actual expression of the endocannabinoid system in patients with and without a family history of psychosis., The Spanish Ministry of Economy and Competitiveness (Ref. ISCIII 2009-2011:PI 080208), the Instituto de Salud Carlos III-European Fund for Regional Development (PI10/01430, PI10/01746, PI11/01977, PI11/02708, 2011/1064, PI12/02077, PI13/02252, PI13/00451 and PI14/01900, PI11/02831), the Centre for Biomedical Research in the Mental Health Network (CIBERSAM), the Health Department of the Government of Navarre (11/101 and 87/2014), the Government of Catalonia, Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement (2014SGR441), the Contract FI-DGR-2013 from the Agència de Gestió d'Ajuts Universitaris i de Recerca, AGAUR (2015 FI_B2 00100 to GM), the Esther Koplowitz Centre (Barcelona), local grants from the Department of Education, Linguistic Policy and Culture of the Basque Country Government, the Basque Foundation for Health Innovation and Research (BIOEF), Madrid Regional Government (S2010/BMD-2422 AGES), European Union Structural Funds and European Union Seventh Framework Program under grant agreements FP7-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7-HEALTH-2009-2.2.1-3-242114 (Project OPTiMISE), FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7-HEALTH-2013-2.2.1-2-602478 (Project METSY); Alicia Koplowitz Foundation, Mutua Madrileña Foundation and the University of the Basque Country (GIC10/80, GIC12/84). The psychiatric research department at Araba University Hospital is supported by the Stanley Research Foundation (03-RC-003).
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

Speech Illusions in People at Clinical High Risk for Psychosis Linked to Clinical Outcome

  • Catalán Alcántara, Ana
  • EU-GEI High-Risk Study Group
Background and hypothesis Around 20% of people at clinical high risk (CHR) for psychosis later develop a psychotic disorder, but it is difficult to predict who this will be. We assessed the incidence of hearing speech (termed speech illusions [SIs]) in noise in CHR participants and examined whether this was associated with adverse clinical outcomes. Study design At baseline, 344 CHR participants and 67 healthy controls were presented with a computerized white noise task and asked whether they heard speech, and whether speech was neutral, affective, or whether they were uncertain about its valence. After 2 years, we assessed whether participants transitioned to psychosis, or remitted from the CHR state, and their functioning. Study results CHR participants had a lower sensitivity to the task. Logistic regression revealed that a bias towards hearing targets in stimuli was associated with remission status (OR = 0.21, P = 042). Conversely, hearing SIs with uncertain valence at baseline was associated with reduced likelihood of remission (OR = 7.72. P = .007). When we assessed only participants who did not take antipsychotic medication at baseline, the association between hearing SIs with uncertain valence at baseline and remission likelihood remained (OR = 7.61, P = .043) and this variable was additionally associated with a greater likelihood of transition to psychosis (OR = 5.34, P = .029). Conclusions In CHR individuals, a tendency to hear speech in noise, and uncertainty about the affective valence of this speech, is associated with adverse outcomes. This task could be used in a battery of cognitive markers to stratify CHR participants according to subsequent outcomes., The European Network of National Schizophrenia Networks Studying Gene Environment Interactions (EU-GEI) Project is funded by grant agreement HEALTH-F2- 2010-241909 (Project EU-GEI) from the European Community’s Seventh Framework Programme. Additional support was provided by a Medical Research Council Fellowship to M Kempton (grant MR/J008915/1), and by the Ministerio de Ciencia, Innovación e Universidades to N Barrantes-Vidal (project PSI2017-87512-C2-1-R).
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

Polygenic contribution to the relationship of loneliness and social isolation with schizophrenia

  • Andreu-Bernabeu, Álvaro
  • Díaz Caneja, Covadonga
  • Costas, Javier
  • de Hoyos, Lucía
  • Stella, Carol
  • Gurriarán, Xaquín
  • Alloza, Clara
  • Fañanás, Lourdes
  • Bobes, Julio
  • González Pinto Arrillaga, Ana María
  • Crespo Facorro, Benedicto
  • Martorell, Lourdes
  • Vilella, Elisabet
  • Muntané, Gerard
  • Nacher, Juan
  • Moltó, María Dolores
  • Aguilar, Eduardo Jesús
  • Parellada, Mara
  • Arango, Celso
  • González Peñas, Javier
[EN] Previous research suggests an association of loneliness and social isolation (LNL-ISO) with schizophrenia. Here, we demonstrate a LNL-ISO polygenic score contribution to schizophrenia risk in an independent case-control sample (N=3,488). We then subset schizophrenia predisposing variation based on its effect on LNL-ISO. We find that genetic variation with concordant effects in both phenotypes shows significant SNP-based heritability enrichment, higher polygenic contribution in females, and positive covariance with mental disorders such as depression, anxiety, attention-deficit hyperactivity disorder, alcohol dependence, and autism. Conversely, genetic variation with discordant effects only contributes to schizophrenia risk in males and is negatively correlated with those disorders. Mendelian randomization analyses demonstrate a plausible bi-directional causal relationship between LNL-ISO and schizophrenia, with a greater effect of LNL-ISO liability on schizophrenia than vice versa. These results illustrate the genetic footprint of LNL-ISO on schizophrenia., This work was supported by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI17/00997, PI19/01024, PI20/00721), co-financed by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN), and FP7- HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz, and Fundación Mutua Madrileña. We are grateful to Paloma Pantoja for her assistance in the design of the figures. A.A.-B. holds a Rio Hortega Grant from Instituto de Salud Carlos III (CM20/00114). C.M.D.-C. holds a Juan Rodés Grant from Instituto de Salud Carlos III (JR19/00024).
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Opposite cannabis-cognition associations in psychotic patients depending on family history

  • González-Pinto, Ana
  • González Ortega, Itxaso
  • Alberich, Susana
  • Ruiz de Azúa, Sonia
  • Bernardo Arroyo, Miquel
  • Bioque Alcázar, Miquel
  • Cabrera, Bibiana
  • Corripio, Iluminada
  • Arango, Celso
  • Lobo, Antonio
  • Sánchez-Torres, Ana M.
  • Cuesta, Manuel J.
  • PEPs Group
The objective of this study is to investigate cognitive performance in a first-episode psycho- sis sample, when stratifying the interaction by cannabis use and familial or non-familial psy- chosis. Hierarchical-regression models were used to analyse this association in a sample of 268 first-episode psychosis patients and 237 controls. We found that cannabis use was associated with worse working memory, regardless of family history. However, cannabis use was clearly associated with worse cognitive performance in patients with no family his- tory of psychosis, in cognitive domains including verbal memory, executive function and global cognitive index, whereas cannabis users with a family history of psychosis performed better in these domains. The main finding of the study is that there is an interaction between cannabis use and a family history of psychosis in the areas of verbal memory, executive function and global cognition: that is, cannabis use is associated with a better performance in patients with a family history of psychosis and a worse performance in those with no fam- ily history of psychosis. In order to confirm this hypothesis, future research should explore the actual expression of the endocannabinoid system in patients with and without a family history of psychosis
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Polygenic contribution to the relationship of loneliness and social isolation with schizophrenia

  • Andreu-Bernabeu, Álvaro
  • Díaz-Caneja, Covadonga M.
  • Costas, Javier
  • De Hoyos, Lucía
  • Stella, Carol
  • Gurriarán, Xaquín
  • Alloza, Clara
  • Fañanás Saura, Lourdes
  • Bobes García, Julio
  • González-Pinto, Ana
  • Crespo-Facorro, Benedicto
  • Martorell, Lourdes
  • Vilella, Elisabet
  • Muntané, Gerard
  • Nacher, Juan
  • Moltó, M. Dolors
  • Aguilar, Eduardo Jesús
  • Parellada, Mara
  • Arango López, Celso
  • González-Peñas, Javier
Previous research suggests an association of loneliness and social isolation (LNL-ISO) with schizophrenia. Here, we demonstrate a LNL-ISO polygenic score contribution to schizophrenia risk in an independent case-control sample (N = 3,488). We then subset schizophrenia predisposing variation based on its effect on LNL-ISO. We find that genetic variation with concordant effects in both phenotypes shows significant SNP-based heritability enrichment, higher polygenic contribution in females, and positive covariance with mental disorders such as depression, anxiety, attention-deficit hyperactivity disorder, alcohol dependence, and autism. Conversely, genetic variation with discordant effects only contributes to schizophrenia risk in males and is negatively correlated with those disorders. Mendelian randomization analyses demonstrate a plausible bi-directional causal relationship between LNL-ISO and schizophrenia, with a greater effect of LNL-ISO liability on schizophrenia than vice versa. These results illustrate the genetic footprint of LNL-ISO on schizophrenia.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Altered structural brain asymmetry in autism spectrum disorder in a study of 54 datasets

  • Postema, Merel C.
  • van Rooij, Daan
  • Anagnostou, Evdokia
  • Arango, Celso
  • Auzias, Guillaume
  • Behrmann, Marlene
  • Filho, Geraldo Busatto
  • Calderoni, Sara
  • Calvo Escalona, Rosa
  • Daly, Eileen
  • Deruelle, Christine
  • Di Martino, Adriana
  • Dinstein, Illan
  • Duran, Fabio Luis S.
  • Durston, Sarah
  • Ecker, Christine
  • Ehrlich, Stefan
  • Fair, Damien
  • Fedor, Jennifer
  • Feng, Xin
  • FitzGerald, Jackie
  • Floris, Dorothea L.
  • Freitag, Christine M.
  • Gallagher, Louise
  • Glahn, David C.
  • Gori, Ilaria
  • Haar, Shlomi
  • Hoekstra, Liesbeth
  • Jahanshad, Neda
  • Jalbrzikowski, Maria
  • Janssen, Joost
  • King, Joseph A.
  • Kong, Xiang-Zhen
  • Lázaro García, Luisa
  • Lerch, Jason P.
  • Luna, Beatriz
  • Martinho, Mauricio M.
  • McGrath, Jane
  • Medland, Sarah E.
  • Muratori, Filippo
Altered structural brain asymmetry in autism spectrum disorder (ASD) has been reported. However, findings have been inconsistent, likely due to limited sample sizes. Here we investigated 1,774 individuals with ASD and 1,809 controls, from 54 independent data sets of the ENIGMA consortium. ASD was significantly associated with alterations of cortical thickness asymmetry in mostly medial frontal, orbitofrontal, cingulate and inferior temporal areas, and also with asymmetry of orbitofrontal surface area. These differences generally involved reduced asymmetry in individuals with ASD compared to controls. Furthermore, putamen volume asymmetry was significantly increased in ASD. The largest case-control effect size was Cohen's d = -0.13, for asymmetry of superior frontal cortical thickness. Most effects did not depend on age, sex, IQ, severity or medication use. Altered lateralized neurodevelopment may therefore be a feature of ASD, affecting widespread brain regions with diverse functions. Large-scale analysis was necessary to quantify subtle alterations of brain structural asymmetry in ASD.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

White noise speech illusions: a trait-dependent risk marker for psychotic disorder?

  • Schepers, Elaine
  • Lousberg, Richel
  • Guloksuz, Sinan
  • Pries, Lotta-Katrin
  • Delespaul, Philippe
  • Kenis, Gunter
  • Luykx, Jurjen J.
  • Lin, Bochao D.
  • Richards, Alexander L.
  • Akdede, Berna
  • Binbay, Tolga
  • Altınyazar, Vesile
  • Yalınçetin, Berna
  • Gümüş-Akay, Güvem
  • Cihan, Burçin
  • Soygür, Haldun
  • Ulas, Halis
  • Cankurtaran, Eylem Sahin
  • Bernardo Arroyo, Miquel
  • Cabrera Llorca, Bibiana
  • Kaymak, Semra Ulusoy
  • Mihaljevic, Marina M.
  • Petrovic, Sanja Andric
  • Mirjanic, Tijana
  • Bernardo Arroyo, Miquel
  • Bobes García, Julio
  • Sáiz Martínez, Pilar Alejandra
  • García-Portilla González, María Paz, 1962-
  • Sanjuan, Julio
  • Aguilar, Eduardo
  • Jiménez López, Estela
  • Arrojo, Manuel
  • Carracedo Álvarez, Ángel
  • López, Gonzalo
  • González Peñas, Javier
  • Parellada, Mara
  • Maric, Nadja P.
  • Atbaşoğlu, Cem
  • Ucok, Alp
  • Alptekin, Köksal
  • Can Saka, Meram
  • Arango, Celso
  • Rutten, Bart P.F.
  • van Os, Jim
Introduction: White noise speech illusions index liability for psychotic disorder in case-control comparisons. In the current study, we examined i) the rate of white noise speech illusions in siblings of patients with psychotic disorder and ii) to what degree this rate would be contingent on exposure to known environmental risk factors (childhood adversity and recent life events) and level of known endophenotypic dimensions of psychotic disorder [psychotic experiences assessed with the Community Assessment of Psychic Experiences (CAPE) scale and cognitive ability]. Methods: The white noise task was used as an experimental paradigm to elicit and measure speech illusions in 1,014 patients with psychotic disorders, 1,157 siblings, and 1,507 healthy participants. We examined associations between speech illusions and increasing familial risk (control -> sibling -> patient), modeled as both a linear and a categorical effect, and associations between speech illusions and level of childhood adversities and life events as well as with CAPE scores and cognitive ability scores. Results: While a positive association was found between white noise speech illusions across hypothesized increasing levels of familial risk (controls -> siblings -> patients) [odds ratio (OR) linear 1.11, 95% confidence interval (CI) 1.02-1.21, p = 0.019], there was no evidence for a categorical association with sibling status (OR 0.93, 95% CI 0.79-1.09, p = 0.360). The association between speech illusions and linear familial risk was greater if scores on the CAPE positive scale were higher (p interaction = 0.003; ORlow CAPE positive scale 0.96, 95% CI 0.85-1.07; ORhigh CAPE positive scale 1.26, 95% CI 1.09-1.46); cognitive ability was lower (p interaction < 0.001; ORhigh cognitive ability 0.94, 95% CI 0.84-1.05; ORlow cognitive ability 1.43, 95% CI 1.23-1.68); and exposure to childhood adversity was higher (p interaction < 0.001; ORlow adversity 0.92, 95% CI 0.82-1.04; ORhigh adversity 1.31, 95% CI 1.13-1.52). A similar, although less marked, pattern was seen for categorical patient-control and sibling-control comparisons. Exposure to recent life events did not modify the association between white noise and familial risk (p interaction = 0.232). Conclusion: The association between white noise speech illusions and familial risk is contingent on additional evidence of endophenotypic expression and of exposure to childhood adversity. Therefore, speech illusions may represent a trait-dependent risk marker.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Early Parental Death and Risk of Psychosis in Offspring: A Six-Country Case-Control Study

  • Misra, Supriya
  • Gelaye, Bizu
  • Koenen, Karestan C.
  • Williams, David R.
  • Borba, Christina P.C.
  • Quattrone, Diego
  • Di Forti, Marta
  • La Cascia, Caterina
  • La Barbera, Daniele
  • Tarricone, Ilaria
  • Berardi, Domenico
  • Szöke, Andrei
  • Arango, Celso
  • Tortelli, Andrea
  • de Haan, Lieuwe
  • Velthorst, Eva
  • Bobes García, Julio
  • Bernardo Arroyo, Miquel
  • Sanjuán, Julio
  • Santos, José Luis
  • Arrojo, Manuel
  • Del-Ben, Cristina Marta
  • Menezes, Paulo Rossi
  • Selten, Jean Paul
  • Jones, Peter B.
  • Kirkbride, James B.
  • EU-GEI WP2 Group
  • Rutten, Bart P.F.
  • van Os, Jim
  • Murray, Robin M.
  • Anderson, Charlotte Gayer
  • Morgan, Craig
Evidence for early parental death as a risk factor for psychosis in offspring is inconclusive. We analyzed data from a six-country, case-control study to examine the associations of early parental death, type of death (maternal, paternal, both), and child's age at death with psychosis, both overall and by ethnic group. In fully adjusted multivariable mixed-effects logistic regression models, experiencing early parental death was associated with 1.54-fold greater odds of psychosis (95% confidence interval (CI): 1.23, 1.92). Experiencing maternal death had 2.27-fold greater odds (95% CI: 1.18, 4.37), paternal death had 1.14-fold greater odds (95% CI: 0.79, 1.64), and both deaths had 4.42-fold greater odds (95% CI: 2.57, 7.60) of psychosis compared with no early parental death. Experiencing parental death between 11 and 16 years of age had 2.03-fold greater odds of psychosis than experiencing it before five years of age (95% CI: 1.02, 4.04). In stratified analyses, experiencing the death of both parents had 9.22-fold greater odds of psychosis among minority ethnic groups (95% CI: 2.02-28.02) and no elevated odds among the ethnic majority (odds ratio (OR): 0.96; 95% CI: 0.10-8.97), which could be due in part to the higher prevalence of early parental death among minority ethnic groups but should be interpreted cautiously given the wide confidence intervals.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinacional EU-GEI study

  • Quattrone, Diego
  • Di Forti, Marta
  • Gayer-Anderson, Charlotte
  • Ferraro, Laura
  • Jongsma, Hanna E.
  • Tripoli, Giada
  • La Cascia, Caterina
  • La Barbera, Daniele
  • Tarricone, Ilaria
  • Berardi, Domenico
  • Szöke, Andrei
  • Arango, Celso
  • Lasalvia, Antonio
  • Tortelli, Andrea
  • Llorca, Pierre Michel
  • de Haan, Lieuwe
  • Velthorst, Eva
  • Bobes García, Julio
  • Bernardo Arroyo, Miquel
  • Sanjuán, Julio
  • Arrojo, Manuel
  • Del-Ben, Cristina Marta
  • Menezes, Paulo Rossi
  • Selten, Jean Paul
  • EU-GEI WP2 Group
  • Jones, Peter B.
  • Kirkbride, James B.
  • Richards, Alexander L.
  • O&apos;Donovan, Michael C.
  • Sham, Pak C.
  • Vassos, Evangelos
  • Rutten, Bart P.F.
  • van Os, Jim
  • Morgan, Craig
  • Lewis, Cathryn M.
  • Murray, Robin M.
  • Reininghaus, Ulrich
Background: The value of the nosological distinction between non-affective and affective psychosis has frequently been challenged. We aimed to investigate the transdiagnostic dimensional structure and associated characteristics of psychopathology at First Episode Psychosis (FEP). Regardless of diagnostic categories, we expected that positive symptoms occurred more frequently in ethnic minority groups and in more densely populated environments, and that negative symptoms were associated with indices of neurodevelopmental impairment. Method: This study included 2182 FEP individuals recruited across six countries, as part of the EUropean network of national schizophrenia networks studying Gene-Environment Interactions (EU-GEI) study. Symptom ratings were analysed using multidimensional item response modelling in Mplus to estimate five theory-based models of psychosis. We used multiple regression models to examine demographic and context factors associated with symptom dimensions. Results: A bifactor model, composed of one general factor and five specific dimensions of positive, negative, disorganization, manic and depressive symptoms, best-represented associations among ratings of psychotic symptoms. Positive symptoms were more common in ethnic minority groups. Urbanicity was associated with a higher score on the general factor. Men presented with more negative and less depressive symptoms than women. Early age-at-first-contact with psychiatric services was associated with higher scores on negative, disorganized, and manic symptom dimensions. Conclusions: Our results suggest that the bifactor model of psychopathology holds across diagnostic categories of non-affective and affective psychosis at FEP, and demographic and context determinants map onto general and specific symptom dimensions. These findings have implications for tailoring symptom-specific treatments and inform research into the mood-psychosis spectrum.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Development of Proteomic Prediction Models for Transition to Psychotic Disorder in the Clinical High-Risk State and Psychotic Experiences in Adolescence.

  • Mongan, D.
  • Föcking, M.
  • Healy, C.
  • Susai, S. R.
  • Heurich, M.
  • Wynne, K.
  • Nelson, B.
  • McGorry, P. D.
  • Amminger, G. P.
  • Nordentoft, M.
  • Krebs, M. O.
  • Riecher-Rössler, A.
  • Bressan, R A.
  • Barrantes Vidal, Neus
  • Borgwardt, S.
  • Ruhrmann, S.
  • Sachs, S.
  • Pantelis, Christos
  • Van der Gaag, Mark
  • de Haan, L.
  • Valmaggia, L.
  • Pollak, T. A.
  • Kempton, Matthew J.
  • Rutten, B. P. F.
  • Whelan, R.
  • Cannon, M.
  • Zammit, S.
  • Cagney, G.
  • Cotter, D. R.
  • McGuire, P. for the European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI).
  • Rosa de la Cruz, Araceli
Importance: Biomarkers that are predictive of outcomes in individuals at risk of psychosis would facilitate individualized prognosis and stratification strategies. Objective: To investigate whether proteomic biomarkers may aid prediction of transition to psychotic disorder in the clinical high-risk (CHR) state and adolescent psychotic experiences (PEs) in the general population. Design, Setting, and Participants: This diagnostic study comprised 2 case-control studies nested within the European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) and the Avon Longitudinal Study of Parents and Children (ALSPAC). EU-GEI is an international multisite prospective study of participants at CHR referred from local mental health services. ALSPAC is a United Kingdom-based general population birth cohort. Included were EU-GEI participants who met CHR criteria at baseline and ALSPAC participants who did not report PEs at age 12 years. Data were analyzed from September 2018 to April 2020. Main Outcomes and Measures: In EU-GEI, transition status was assessed by the Comprehensive Assessment of At-Risk Mental States or contact with clinical services. In ALSPAC, PEs at age 18 years were assessed using the Psychosis-Like Symptoms Interview. Proteomic data were obtained from mass spectrometry of baseline plasma samples in EU-GEI and plasma samples at age 12 years in ALSPAC. Support vector machine learning algorithms were used to develop predictive models. Results: The EU-GEI subsample (133 participants at CHR (mean [SD] age, 22.6 [4.5] years; 68 [51.1%] male) comprised 49 (36.8%) who developed psychosis and 84 (63.2%) who did not. A model based on baseline clinical and proteomic data demonstrated excellent performance for prediction of transition outcome (area under the receiver operating characteristic curve [AUC], 0.95; positive predictive value [PPV], 75.0%; and negative predictive value [NPV], 98.6%). Functional analysis of differentially expressed proteins implicated the complement and coagulation cascade. A model based on the 10 most predictive proteins accurately predicted transition status in training (AUC, 0.99; PPV, 76.9%; and NPV, 100%) and test (AUC, 0.92; PPV, 81.8%; and NPV, 96.8%) data. The ALSPAC subsample (121 participants from the general population with plasma samples available at age 12 years (61 [50.4%] male) comprised 55 participants (45.5%) with PEs at age 18 years and 61 (50.4%) without PEs at age 18 years. A model using proteomic data at age 12 years predicted PEs at age 18 years, with an AUC of 0.74 (PPV, 67.8%; and NPV, 75.8%). Conclusions and Relevance: In individuals at risk of psychosis, proteomic biomarkers may contribute to individualized prognosis and stratification strategies. These findings implicate early dysregulation of the complement and coagulation cascade in the development of psychosis outcomes.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Childhood Maltreatment, Educational Attainment, and IQ: Findings From a Multicentric Case-control Study of First-episode Psychosis (EU-GEI)

  • Sideli, Lucia
  • Schimmenti, Adriano
  • La Barbera, Daniele
  • La Cascia, Caterina
  • Ferraro, Laura
  • Aas, Monica
  • Alameda, Luis
  • Velthorst, Eva
  • Fisher, Helen L.
  • Caretti, Vincenzo
  • Trotta, Giulia
  • Tripoli, Giada
  • Quattrone, Diego
  • Gayer-Anderson, Charlotte
  • Seminerio, Fabio
  • Sartorio, Crocettarachele
  • Marrazzo, Giovanna
  • Lasalvia, Antonio
  • Tosato, Sarah
  • Tarricone, Ilaria
  • Berardi, Domenico
  • D'Andrea, Giuseppe
  • Arango, Celso
  • Arrojo, Manuel
  • Bernardo, Miguel
  • Bobes, Julio
  • Sanjuán, Julio
  • Santos, José Luis
  • Menezes, Paulo Rossi
  • Del-Ben, Cristina Marta
  • Jongsma, Hannah E.
  • Jones, Peter B.
  • Kirkbride, James B.
  • Llorca, Pierre-Michel
  • Tortelli, Andrea
  • Pignon, Baptiste
  • de Haan, Lieuwe
  • Selten, Jean-Paul
  • Van Os, Jim
  • Rutten, Bart P. F.
  • Di Forti, Marta
  • Morgan, Craig
  • Murray, Robin M.
[Background and hypothesis] Evidence suggests that childhood maltreatment (ie, childhood abuse and childhood neglect) affects educational attainment and cognition. However, the association between childhood maltreatment and Intelligence Quotient (IQ) seems stronger among controls compared to people with psychosis. We hypothesised that: the association between childhood maltreatment and poor cognition would be stronger among community controls than among people with first-episode of psychosis (FEP); compared to abuse, neglect would show stronger associations with educational attainment and cognition; the association between childhood maltreatment and IQ would be partially accounted for by other risk factors; and the association between childhood maltreatment, educational attainment, and IQ would be stronger among patients with affective psychoses compared to those with nonaffective psychoses., [Study Design] 829 patients with FEP and 1283 community controls from 16 EU-GEI sites were assessed for child maltreatment, education attainment, and IQ., [Study Results] In both the FEP and control group, childhood maltreatment was associated with lower educational attainment. The association between childhood maltreatment and lower IQ was robust to adjustment for confounders only among controls. Whereas childhood neglect was consistently associated with lower attainment and IQ in both groups, childhood abuse was associated with IQ only in controls. Among both patients with affective and nonaffective psychoses, negative associations between childhood maltreatment and educational attainment were observed, but the crude association with IQ was only evident in affective psychoses., [Conclusions] Our findings underscore the role of childhood maltreatment in shaping academic outcomes and cognition of people with FEP as well as controls., The EU-GEI Study is funded by grant agreement HEALTH-F2-2010-241909 (Project EU-GEI) from the European Community’s Seventh Framework Programme, and Grant 2012/0417-0 from the São Paulo Research Foundation. B.P.F. Rutten is funded by a VIDI award (no. 91.718.336) from the Netherlands Scientific Organization. H. L. Fisher, C. Gayer-Anderson, and C. Morgan are supported by the Economic and Social Research Council (ESRC) Centre for Society and Mental Health at King’s College London [ES/S012567/1]. C. Arango has received support by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements, FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7- HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso and Fundación Alicia Koplowitz. J.B. Kirkbride is supported by the NIHR University College London Hospital Biomedical Research Centre., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia

  • Pardiñas, Antonio F.
  • Smart, Sophie E.
  • Willcocks, Isabella R.
  • Holmans, Peter A.
  • Dennison, Charlotte A.
  • Lynham, Amy
  • Legge, Sophie E.
  • Baune, Bernhard T.
  • Bigdeli, Tim B.
  • Cairns, Murray J.
  • Corvin, Aiden
  • Fanous, Ayman H.
  • Frank, Josef
  • Kelly, Brian
  • McQuillin, Andrew
  • Melle, Ingrid
  • Mortensen, Preben B.
  • Mowry, Bryan J.
  • Pato, Carlos N.
  • Periyasamy, Sathish
  • Rietschel, Marcella
  • Rujescu, Dan
  • Simonsen, Carmen
  • St Clair, David
  • Tooney, Paul A.
  • Wu, Jing Qin
  • Andreassen, Ole A.
  • Kowalec, Kaarina
  • Sullivan, Patrick F.
  • Murray, Robin M.
  • Owen, Michael J.
  • MacCabe, James H.
  • O'Donovan, Michael C.
  • Walters, James T. R.
  • Genetics Workstream of the Schizophrenia Treatment Resistance and Therapeutic Advances (STRATA)
  • Consortium and the Schizophrenia Working Group of the Psychiatric Genomics Consortium (PGC)
[Importance] About 20% to 30% of people with schizophrenia have psychotic symptoms that do not respond adequately to first-line antipsychotic treatment. This clinical presentation, chronic and highly disabling, is known as treatment-resistant schizophrenia (TRS). The causes of treatment resistance and their relationships with causes underlying schizophrenia are largely unknown. Adequately powered genetic studies of TRS are scarce because of the difficulty in collecting data from well-characterized TRS cohorts., [Objective] To examine the genetic architecture of TRS through the reassessment of genetic data from schizophrenia studies and its validation in carefully ascertained clinical samples., [Design, Setting, and Participants] Two case-control genome-wide association studies (GWASs) of schizophrenia were performed in which the case samples were defined as individuals with TRS (n = 10 501) and individuals with non-TRS (n = 20 325). The differences in effect sizes for allelic associations were then determined between both studies, the reasoning being such differences reflect treatment resistance instead of schizophrenia. Genotype data were retrieved from the CLOZUK and Psychiatric Genomics Consortium (PGC) schizophrenia studies. The output was validated using polygenic risk score (PRS) profiling of 2 independent schizophrenia cohorts with TRS and non-TRS: a prevalence sample with 817 individuals (Cardiff Cognition in Schizophrenia [CardiffCOGS]) and an incidence sample with 563 individuals (Genetics Workstream of the Schizophrenia Treatment Resistance and Therapeutic Advances [STRATA-G])., [Main Outcomes and Measures] GWAS of treatment resistance in schizophrenia. The results of the GWAS were compared with complex polygenic traits through a genetic correlation approach and were used for PRS analysis on the independent validation cohorts using the same TRS definition., [Results] The study included a total of 85 490 participants (48 635 [56.9%] male) in its GWAS stage and 1380 participants (859 [62.2%] male) in its PRS validation stage. Treatment resistance in schizophrenia emerged as a polygenic trait with detectable heritability (1% to 4%), and several traits related to intelligence and cognition were found to be genetically correlated with it (genetic correlation, 0.41-0.69). PRS analysis in the CardiffCOGS prevalence sample showed a positive association between TRS and a history of taking clozapine (r2 = 2.03%; P = .001), which was replicated in the STRATA-G incidence sample (r2 = 1.09%; P = .04)., [Conclusions and Relevance] In this GWAS, common genetic variants were differentially associated with TRS, and these associations may have been obscured through the amalgamation of large GWAS samples in previous studies of broadly defined schizophrenia. Findings of this study suggest the validity of meta-analytic approaches for studies on patient outcomes, including treatment resistance., This work was supported by Medical Research Council Centre grant MR/L010305/1, Medical Research Council Program grant MR/P005748/1, and Medical Research Council Project grants MR/L011794/1 and MC_PC_17212 to Cardiff University and by the National Centre for Mental Health, funded by the Welsh Government through Health and Care Research Wales. This work acknowledges the support of the Supercomputing Wales project, which is partially funded by the European Regional Development Fund via the Welsh Government. Dr Pardiñas was supported by an Academy of Medical Sciences Springboard Award (SBF005\1083). Dr Andreassen was supported by the Research Council of Norway (grants 283798, 262656, 248980, 273291, 248828, 248778, and 223273); KG Jebsen Stiftelsen, South-East Norway Health Authority, and the European Union’s Horizon 2020 Research and Innovation Programme (grant 847776). Dr Ajnakina was supported by an National Institute for Health Research postdoctoral fellowship (PDF-2018-11-ST2-020). Dr Joyce was supported by the University College London Hospitals/UCL University College London Biomedical Research Centre. Dr Kowalec received funding from the European Union’s Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement (793530) from the government of Canada Banting postdoctoral fellowship programme and the University of Manitoba. Dr Sullivan was supported by the Swedish Research Council (Vetenskapsrådet, D0886501), the European Union’s Horizon 2020 programme (COSYN, 610307) and the US National Institute of Mental Health (U01 MH109528 and R01 MH077139). The Psychiatric Genomics Consortium was partly supported by the National Institute Of Mental Health (grants R01MH124873). The Sweden Schizophrenia Study was supported by the National Institute Of Mental Health (grant R01MH077139). The STRATA consortium was supported by a Stratified Medicine Programme grant to Dr MacCabe from the Medical Research Council (grant MR/L011794/1), which funded the research and supported Drs Pardiñas, Smart, Kassoumeri, Murray, Walters, and MacCabe. Dr Smart was supported by a Collaboration for Leadership in Applied Health Research and Care South London at King’s College Hospital National Health Service Foundation Trust. The AESOP (US) cohort was funded by the UK Medical Research Council (grant G0500817). The Belfast (UK) cohort was funded by the Research and Development Office of Northern Ireland. The Bologna (Italy) cohort was funded by the European Community’s Seventh Framework program (HEALTH-F2-2010–241909, project EU-GEI). The Genetics and Psychosis project (London, UK) cohort was funded by the UK National Institute of Health Research Specialist Biomedical Research Centre for Mental Health, South London and the Maudsley National Health Service Mental Health Foundation Trust (SLAM) and the Institute of Psychiatry, Psychology, and Neuroscience at King’s College London; Psychiatry Research Trust; Maudsley Charity Research Fund; and the European Community’s Seventh Framework program (HEALTH-F2-2009-241909, project EU-GEI). The Lausanne (Switzerland) cohort was funded by the Swiss National Science Foundation (grants 320030_135736/1, 320030-120686, 324730-144064, 320030-173211, and 171804); the National Center of Competence in Research Synaptic Bases of Mental Diseases from the Swiss National Science Foundation (grant 51AU40_125759); and Fondation Alamaya. The Oslo (Norway) cohort was funded by the Research Council of Norway (grant 223273/F50, under the Centers of Excellence funding scheme, 300309, 283798) and the South-Eastern Norway Regional Health Authority (grants 2006233, 2006258, 2011085, 2014102, 2015088, and 2017-112). The Paris (France) cohort was funded by European Community’s Seventh Framework program (HEALTH-F2-2010–241909, project EU-GEI). The Prague (Czech Republic) cohort was funded by the Ministry of Health of the Czech Republic (grant NU20-04-00393). The Santander (Spain) cohort was funded by the following grants to Dr Crespo-Facorro: Instituto de Salud Carlos III (grants FIS00/3095, PI020499, PI050427, and PI060507), Plan Nacional de Drogas Research (grant 2005-Orden sco/3246/2004), SENY Fundatio Research (grant 2005-0308007), Fundacion Marques de Valdecilla (grant A/02/07, API07/011) and Ministry of Economy and Competitiveness and the European Fund for Regional Development (grants SAF2016-76046-R and SAF2013-46292-R). The West London (UK) cohort was funded by The Wellcome Trust (grants 042025, 052247, and 064607)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

In vivo white matter microstructure in adolescents with early-onset psychosis: a multi-site mega-analysis

  • Barth, Claudia
  • Crespo-Facorro, Benedicto
  • Tordesillas-Gutiérrez, Diana
et al., Emerging evidence suggests brain white matter alterations in adolescents with early-onset psychosis (EOP; age of onset <18 years). However, as neuroimaging methods vary and sample sizes are modest, results remain inconclusive. Using harmonized data processing protocols and a mega-analytic approach, we compared white matter microstructure in EOP and healthy controls using diffusion tensor imaging (DTI). Our sample included 321 adolescents with EOP (median age = 16.6 years, interquartile range (IQR) = 2.14, 46.4% females) and 265 adolescent healthy controls (median age = 16.2 years, IQR = 2.43, 57.7% females) pooled from nine sites. All sites extracted mean fractional anisotropy (FA), mean diffusivity (MD), radial diffusivity (RD), and axial diffusivity (AD) for 25 white matter regions of interest per participant. ComBat harmonization was performed for all DTI measures to adjust for scanner differences. Multiple linear regression models were fitted to investigate case-control differences and associations with clinical variables in regional DTI measures. We found widespread lower FA in EOP compared to healthy controls, with the largest effect sizes in the superior longitudinal fasciculus (Cohen’s d = 0.37), posterior corona radiata (d = 0.32), and superior fronto‐occipital fasciculus (d = 0.31). We also found widespread higher RD and more localized higher MD and AD. We detected significant effects of diagnostic subgroup, sex, and duration of illness, but not medication status. Using the largest EOP DTI sample to date, our findings suggest a profile of widespread white matter microstructure alterations in adolescents with EOP, most prominently in male individuals with early-onset schizophrenia and individuals with a shorter duration of illness., ENIGMA Core: U.S. National Institutes of Health grants, R01 EB015611, U54 EB020403, R01 MH116147, R01 MH117601, R01 MH121246, S10 OD023696. YTOP: The Research Council of Norway (223273, 2137000, 250358, 288083); South-Eastern Norway Regional Health Authority (2017112, 2022080); KG Jebsen Stiftelsen (SKGJ-MED-008). MADRID: Celso Arango has received funding from CIBERSAM: Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, co-financed by ERDF Funds from the European Commission, “A way of making Europe”; CIBERSAM; Instituto de Investigación Sanitaria Gregorio Marañón; Madrid Regional Government (B2017/BMD-3740 AGES-CM-2, Youth Employment Operational Program and Youth Employment Initiative); European Social Fund and EU Structural Funds; EU Seventh Framework Program under grant agreements FP7-HEALTH-2009-2.2.1-2-241909, FP7-HEALTH-2009-2.2.1-3-242114, FP7-HEALTH-2013-2.2.1-2-602478, and FP7-HEALTH-2013-2.2.1-2-603196; EU H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz and Fundación Mutua Madrileña. Covadonga M. Díaz-Cenaj has received grant support from Instituto de Salud Carlos III (PI17/00481, PI20/00721, JR19/00024). FEMS: This project was supported by an unrestricted grant from AstraZeneca. Michael Berk is supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship (1059660 and APP1156072). SCAPS: The Swedish Research Council (521-2014-3487, 2017-00949); FORMAS (259-2012-31). OXFORD: MRC G0500092. PAFIP: This study was supported by grants from Carlos III Health Institute (IPI17/00402, PI17/01056, PI14/00639 and PI14/00918) cofunded by The European Union through FEDER funds and Fundación Instituto de Investigación Marqués de Valdecilla (NCT0235832 and NCT02534363). No pharmaceutical company has financially supported the study. BARCELONA: Inmaculada Baeza has received research funds from the Spanish Ministry of Health, Instituto de Salud Carlos II, supported by ERDF Funds from the European Comission (PI18/0242 and PI21/0391), “Otra manera de hacer Europa”, and Fundación Alcia Koplowitz. Elena de la Serna has received grant support from Instituto de Salud Carlos III (PI20/00654). Gisela Sugranyes has received research funds from Instituto de Salud Carlos III (PI1800976 and PI2100330), the Alicia Koplowitz Foundation (AKOPLOWITZ20_004), Ajut a la Recerca Pons Bartran (FCRB_PB1_2018) and a Brain and Behaviour Research Foundation NARSAD 2017 Young Investigator Grant (26731). UCLA: NIMH grants U01MH081902, P50MH066286., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Synergistic effects of childhood adversity and polygenic risk in first-episode psychosis: the EU-GEI study

  • Aas, Monica
  • Alameda, Luis
  • Di Forti, Marta
  • Quattrone, Diego
  • Dazzan, Paola
  • Trotta, Antonella
  • Ferraro, Laura
  • Rodríguez, Victoria
  • Vassos, Evangelos
  • Sham, Pak C.
  • Tripoli, Giada
  • La Cascia, Caterina
  • La Barbera, Daniele
  • Tarricone, Ilaria
  • Muratori, Roberto
  • Berardi, Domenico
  • Lasalvia, Antonio
  • Tosato, Sarah
  • Szöke, Andrei
  • Llorca, Pierre-Michel
  • Arango, Celso
  • Tortelli, Andrea
  • Haan, Lieuwe de
  • Velthorst, Eva
  • Bobes, Julio
  • Bernardo, Miguel
  • Sanjuán, Julio
  • Santos, José Luis
  • Arrojo, Manuel
  • Del-Ben, Cristina Marta
  • Menezes, Paulo Rossi
  • Selten, Jean-Paul
  • Jones, Peter B.
  • Jongsma, Hannah E.
  • Kirkbride, James B.
  • Rutten, Bart P. F.
  • Os, Jim van
  • Gayer-Anderson, Charlotte
  • Murray, Robin M.
  • Morgan, Craig
[Background] A history of childhood adversity is associated with psychotic disorder, with an increase in risk according to the number of exposures. However, it is not known why only some exposed individuals go on to develop psychosis. One possibility is pre-existing polygenic vulnerability. Here, we investigated, in the largest sample of first-episode psychosis (FEP) cases to date, whether childhood adversity and high polygenic risk scores for schizophrenia (SZ-PRS) combine synergistically to increase the risk of psychosis, over and above the effect of each alone., [Methods] We assigned a schizophrenia-polygenic risk score (SZ-PRS), calculated from the Psychiatric Genomics Consortium (PGC2), to all participants in a sample of 384 FEP patients and 690 controls from the case–control component of the EU-GEI study. Only participants of European ancestry were included in the study. A history of childhood adversity was collected using the Childhood Trauma Questionnaire (CTQ). Synergistic effects were estimated using the interaction contrast ratio (ICR) [odds ratio (OR)exposure and PRS − ORexposure − ORPRS + 1] with adjustment for potential confounders., [Results] There was some evidence that the combined effect of childhood adversities and polygenic risk was greater than the sum of each alone, as indicated by an ICR greater than zero [i.e. ICR 1.28, 95% confidence interval (CI) −1.29 to 3.85]. Examining subtypes of childhood adversities, the strongest synergetic effect was observed for physical abuse (ICR 6.25, 95% CI −6.25 to 20.88)., [Conclusions] Our findings suggest possible synergistic effects of genetic liability and childhood adversity experiences in the onset of FEP, but larger samples are needed to increase precision of estimates., The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) Project is funded by grant agreement HEALTH-F2-2010-241909 (Project EU-GEI) from the European Community's Seventh Framework Programme. This study was also funded by the South-Eastern Norway Health Authority (no. 2017060), and the NARSAD Young Investigator Award to M. Aas (no. 22388)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Brain ageing in schizophrenia: evidence from 26 international cohorts via the ENIGMA Schizophrenia consortium

  • Constantinides, Constantinos
  • Crespo-Facorro, Benedicto
  • Tordesillas-Gutiérrez, Diana
  • Walton, Esther
C. Constantinides et al., Schizophrenia (SZ) is associated with an increased risk of life-long cognitive impairments, age-related chronic disease, and premature mortality. We investigated evidence for advanced brain ageing in adult SZ patients, and whether this was associated with clinical characteristics in a prospective meta-analytic study conducted by the ENIGMA Schizophrenia Working Group. The study included data from 26 cohorts worldwide, with a total of 2803 SZ patients (mean age 34.2 years; range 18-72 years; 67% male) and 2598 healthy controls (mean age 33.8 years, range 18-73 years, 55% male). Brain-predicted age was individually estimated using a model trained on independent data based on 68 measures of cortical thickness and surface area, 7 subcortical volumes, lateral ventricular volumes and total intracranial volume, all derived from T1-weighted brain magnetic resonance imaging (MRI) scans. Deviations from a healthy brain ageing trajectory were assessed by the difference between brain-predicted age and chronological age (brain-predicted age difference [brain-PAD]). On average, SZ patients showed a higher brain-PAD of +3.55 years (95% CI: 2.91, 4.19; I2 = 57.53%) compared to controls, after adjusting for age, sex and site (Cohen's d = 0.48). Among SZ patients, brain-PAD was not associated with specific clinical characteristics (age of onset, duration of illness, symptom severity, or antipsychotic use and dose). This large-scale collaborative study suggests advanced structural brain ageing in SZ. Longitudinal studies of SZ and a range of mental and somatic health outcomes will help to further evaluate the clinical implications of increased brain-PAD and its ability to be influenced by interventions., The ENIGMA Schizophrenia Working Group acknowledges the National Institutes of Health (NIH) Big Data to Knowledge (BD2K) award for foundational support and consortium development (Grant No. U54 EB020403 to PMT). CC was supported by grant MR/N0137941/1 for the GW4 BIOMED Doctoral Training Partnership awarded to the Universities of Bath, Bristol, Cardiff and Exeter from the Medical Research Council (MRC)/ UK Research & Innovation (UKRI). JHC was supported by a UKRI Innovation Fellowship (MR/R024790/2). LE was supported by Desert-Pacific Mental Illness Research Education and Clinical Center, US, NIH grant R01MH083968-05. TH was funded by the German Research Foundation (DFG grants HA7070/2-2, HA7070/3, HA7070/4 to TH). LH was supported by a Rubicon fellowship (grant number 452020227) provided by The Dutch Research Council (NWO). NJ and LS were supported by NIH grant R01 MH117601. NJ was also supported by NIH grants R01AG059874, R01MH11760. LS was also supported by a National Health and Medical Research Council (NHMRC) Career Development Fellowship (1140764) and a University of Melbourne Dame Kate Campbell fellowship. PMT was supported in part by NIH grant R01 MH116147. EW was supported by the European Union Horizon 2020 research and innovation programme (EarlyCause, grant number 848158). Acknowledgements for the various participating data contributors follow - ASRB: the Australian Schizophrenia Research Bank (ASRB) was supported by NHMRC (Enabling Grant, ID 386500), the Pratt Foundation, Ramsay Health Care, the Viertel Charitable Foundation and the Schizophrenia Research Institute. CP was also supported by a NHMRC Senior Principal Research Fellowship (1105825), an NHMRC L3 Investigator Grant (1196508). CSW was funded by the NSW Ministry of Health, Office of Health and Medical Research and a recipient of a National Health and Medical Research Council (Australia) Principal Research Fellowship (PRF) (#1117079). CAMH: the datasets were generated and shared with support from the CAMH Foundation and the Canadian Institutes of Health Research. CASSI: this study was supported by NHMRC grant 568807 (awarded to CSW and TW). CSW was funded by the NSW Ministry of Health, Office of Health and Medical Research and a recipient of a NHMRC (Australia) Principal Research Fellowship (PRF) (#1117079). COBRE: the study and investigators were supported by NIH grants R01MH118695, R01MH121101, as well as National Science Foundation (NSF) grant 2112455 (awarded to VC). JT (senior author) was supported by NIH grant R01MH121246. EONCKS: all processing of contributed neuroimaging data was conducted on the Centre for High Performance Computing, Cape Town, South Africa. ESO: the study and investigators (AC, FS, DT) was funded by the Ministry of Health, Czech Republic - Conceptual Development of Research Organization (Institute for Clinical and Experimental Medicine – IKEM, IN 00023001), and Ministry of Health of the Czech Republic, grants nr. NU20-04-00393 and NU21-08-00432. FBIRN: The study was supported by National Institutes of Health grant numbers: NIH 1 U24 RR021992 (Function Biomedical Informatics Research Network), NIH 1 U24 RR025736 (Biomedical Informatics Research Network Coordinating). FBIRN data was processed by the UCI High Performance Computing cluster supported by Joseph Farran, Harry Mangalam, and Adam Brenner and the NCRR and the National Center for Advancing Translational Sciences. JT (senior author) was also supported by NIH grant R01MH121246. FIDMAG: this study was supported by Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and the Catalonian Government, Generalitat de Catalunya (2017-SGR-1271 to EP-C from AGAUR). PFC was supported by a Sara Borrell contract (CD19/00149), funded by Instituto de Salud Carlos III, co-funded by the European Union (European Regional Development Fund/European Social Fund [ERDF/ESF], “Investing in your future”). FSLRome: the IRCCS Santa Lucia Foundation of Rome study (FSLRome) was partially supported by the Italian Ministry of Health (RC12-13-14-15A Grant) and by the European Commission ERA-Net NEURON joint transnational calI 2010 (European Research Projects on Mental Disorders: NEUCONNECT). GROUP: This work was supported by the Geestkracht program of the Dutch Health Research Council (ZON-MW, grant number: 10-000-1002), and the European Community’s Seventh Framework Program under grant agreement No. HEALTH-F2-2009-241909 (Project EU-GEI). Huilong: this study was funded by the National Natural Science Foundation of China (81761128021;31671145;81401115;81401133), Beijing Municipal Science & Technology Commission grant (Z141107002514016) and Beijing Natural Science Foundation (7162087, Beijing Municipal Administration of Hospitals Clinical medicine Development of special funding (XMLX201609; zylx201409). IGP: The Imaging Genetics in Psychosis (IGP) study was supported by NHMRC Project Grant APP630471, APP1051673, APP1081603 (awarded to MJG), and the Macquarie University’s ARC Centre of Excellence in Cognition and its Disorders (CE110001021). MJG was supported by an Australian Research Council Future Fellowship (FT0991511; 2009-13) and a R.D. Wright Biomedical Career Development Award from the NHMRC (1061875; 2014-17). IMH: this study was supported by the National Healthcare Group, Singapore (SIG/05004; SIG/05028) and the Singapore Bioimaging Consortium (RP C009/06) research grants (awarded to KS). iRELATE: this study was supported by grants to GD from the European Research Council (ERC-2015-STG-677467) and Science Foundation Ireland (SFI-16/ERCS/3787). JBNU: YC was supported by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant no. HI18C2383). Madrid: this research was supported by the Spanish Ministry of Science and Innovation; Instituto de Salud Carlos III (grants SAM16PE07CP1, PI16/02012, and PI19/01024 awarded to CAra; PI17/01249 awarded JJ; and PI17/00481, JR19/00024 and PI20/00721 awarded to CMD-C), co-financed by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM; Madrid Regional Government (B2017/BMD-3740 AGES-CM-2 awarded to CAra), European Union Structural Funds; European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7- HEALTH-2013-2.2.1-2-602478 (Project METSY) awarded to Cara; and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS awarded to CAra), Fundación Familia Alonso and Fundación Alicia Koplowitz. MCIC: this work was primarily supported by the Department of Energy (DE-FG02- 99ER62764) and the Mind Research Network. VC was also supported by NSF (grant no. 2112455) and NIH (grant no. R01MH118695, R01MH121101). MPRC: support was received from NIH grants R01MH123163, R01EB015611, R01NS114628 (awarded to PK). PAFIP: this study has been funded by Instituto de Salud Carlos III through the project PI17/01056 (co-funded by ERDF/ESF “A way to make Europe”/“Investing in your future”). RSCZ: the study was supported by National Institutes of Health grant number: NIMH R21MH097196 to TGMvE. SCORE: this study was supported in part by grant 3232BO_119382 from the Swiss National Science Foundation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Large-scale analysis of structural brain asymmetries in schizophrenia via the ENIGMA consortium

  • Schijven, Dick
  • Postema, Merel C.
  • Fukunaga, Masaki
  • Tordesillas-Gutiérrez, Diana
  • Crespo-Facorro, Benedicto
  • Francks, Clyde
ENIGMA consortium: et al., Left-right asymmetry is an important organizing feature of the healthy brain that may be altered in schizophrenia, but most studies have used relatively small samples and heterogeneous approaches, resulting in equivocal findings. We carried out the largest case-control study of structural brain asymmetries in schizophrenia, with MRI data from 5,080 affected individuals and 6,015 controls across 46 datasets, using a single image analysis protocol. Asymmetry indexes were calculated for global and regional cortical thickness, surface area, and subcortical volume measures. Differences of asymmetry were calculated between affected individuals and controls per dataset, and effect sizes were meta-analyzed across datasets. Small average case-control differences were observed for thickness asymmetries of the rostral anterior cingulate and the middle temporal gyrus, both driven by thinner left-hemispheric cortices in schizophrenia. Analyses of these asymmetries with respect to the use of antipsychotic medication and other clinical variables did not show any significant associations. Assessment of age- and sex-specific effects revealed a stronger average leftward asymmetry of pallidum volume between older cases and controls. Case-control differences in a multivariate context were assessed in a subset of the data (N = 2,029), which revealed that 7% of the variance across all structural asymmetries was explained by case-control status. Subtle case-control differences of brain macrostructural asymmetry may reflect differences at the molecular, cytoarchitectonic, or circuit levels that have functional relevance for the disorder. Reduced left middle temporal cortical thickness is consistent with altered left-hemisphere language network organization in schizophrenia., The ENIGMA project is in part supported by the National Institute of Biomedical Imaging and Bioengineering of the NIH (U54EB020403). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Individual Funding Sources: D.S., M.C.P., S.E.F., and C.F.: Max Planck Society (Germany). R.A.-A.: Miguel Servet contract from the Carlos III Health Institute (CP18/00003). J.V.-B.: Instituto de Investigación Sanitaria Valdecilla (IDIVAL) (INT/A21/10, INT/A20/04). D.A.: South-Eastern Norway Regional Health Authority (2019107, 2020086). L.T.W.: Research Council of Norway (223273, 300767), South-Eastern Norway Regional Health Authority (2019101), and European Research Council under the European Union’s Horizon 2020 Research and Innovation Program (ERC StG, 802998). O.A.A.: Research Council of Norway (223273, 275054), KG Jebsen Stiftelsen, South East Norway Health Authority (2017-112, 2019-108). P.K.: NIH (R01MH123163, R01EB015611). M.J.G.: National Health and Medical Research Council (NHMRC) (630471, 1051672, 1081603). C.P.: NHMRC Senior Principal Research Fellowship (1105825), NHMRC L3 Investigator Grant (1196508). V.D.C.: NIH (R01MH118695), NSF (2112455). J.M.F.: Senior Research Career Scientist Award, Department of Veterans Affairs. P.F.-C.: Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Instituto de Salud Carlos III, cofunded by European Union (European Regional Development Fund (ERDF)/European Social Fund (ESF), “Investing in your future”): Sara Borrell Research contract (CD19/00149). G.S.: Italian Ministry of Health (RC17-18-19-20-21/A). A.N.V.: National Institute of Mental Health (NIMH), Canadian Institutes of Health Research (CIHR), Canada Foundation for Innovation, Centre for Addiction and Mental Health (CAMH) Foundation, University of Toronto. Y.-C.C.: Korean Mental Health Technology R&D Project (HL19C0015) and Korea Health Technology R&D Project through the Korea Health Industry Development Institute (HI18C2383), funded by the Ministry of Health & Welfare, Republic of Korea. J.M.S.: NIH (1P20RR021938-01). A.R.M.: NIH (P30GM122734, R01MH101512). C.M.D.-C.: Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (PI17/00481, PI20/00721, JR19/00024). S. Cervenka: Swedish Research Council (523-2014-3467). M. Kirschner: Swiss National Science Foundation (SNSF) (P2SKP3_178175). T.H.: CIHR (142255), Ministry of Health of the Czech Republic (16-32791A, NU20-04-00393), Brain & Behavior Research Foundation (BBRF) Young and Independent Investigator Awards. A. James: Medical Research Council (MRC) (G0500092). P.H.: NARSAD grant from the BBRF (28445), Research Grant from the Novartis Foundation (20A058). R.C.G.: NIH (1R01MH117014, 1R01MH119219). N.J.: NIH (R01MH117601). S.E.M.: NHMRC (APP1172917). J.A.T.: NIH (R01MH1​21246). Dataset-Specific Funding Sources and Acknowledgments: AMC: Supported by grants from The Netherlands Organisation for Health Research and Development (ZonMw) (3160007, 91676084, 31160003, 31180002, 31000056, 2812412, 100001002, 100002034), the Dutch Research Council (NWO) (90461193, 40007080, 48004004, 40003330), the Amsterdam Brain Imaging Platform, Neuroscience Campus Amsterdam, and the Dutch Brain Foundation. Processing with FreeSurfer was performed on the Dutch e-Science Grid through BiG Grid project and COMMIT project “e-Biobanking with imaging for healthcare,” which are funded by the NWO. ASRB: Australian Schizophrenia Research Bank, supported by the NHMRC (Enabling Grant, 386500), the Pratt Foundation, Ramsay Health Care, the Viertel Charitable Foundation, and the Schizophrenia Research Institute. Chief Investigators for ASRB were S.V.C., P.T.M., B.J.M., U.S., R.J.S., V.J.C., F.A.H., C.P., Assen Jablensky. We thank C.M.L., the ASRB Manager, and acknowledge the help of Jason Bridge for ASRB database queries. CAMH: Datasets were collected and shared with support from the CAMH Foundation and the CIHR. CASSI (Cognitive and Affective Symptoms in Schizophrenia Intervention): Supported by the University of New South Wales School of Psychiatry, the NHMRC (568807), Neuroscience Research Australia, the Schizophrenia Research Institute utilizing infrastructure funding from NSW Ministry of Health, the Macquarie Group Foundation, and the ASRB (see above). CIAM (Cortical Inhibition and Attentional Modulation): The CIAM group (PI: F.M.H.) was supported by the University Research Committee, University of Cape Town; South African National Research Foundation (NRF); South African Medical Research Council (SA MRC). CLING (Clinical Neuroscience Goettingen): Sample data collection partially supported by the Deutsche Forschungsgemeinschaft (DFG) (GR1950/5-1 to O.G.). COBRE (Center for Biomedical Research Excellence): Supported by NIH (R01EB006841, P20GM103472, 5R01MH094524 to V.D.C. and J.A.T. R01AA021771 and P50AA022534 to J.M.S.), and the NSF (1539067). EdinburghEHRS: Funded by the MRC (G9226254, G9825423), the Dr. Mortimer and Theresa Sackler Foundation. EdinburghFunc: Funded by the MRC Clinical Training Fellowship (G84/5699) and Health Foundation Clinician Scientist Fellowship (2268/4295). EdinburghSFMH: Funded by an award from the Translational Medicine Research Collaboration (NS_EU_166), Scottish Enterprise, Pfizer, the Dr. Mortimer and Theresa Sackler Foundation. The University of Edinburgh is a charitable body, registered in Scotland, with registration number SC005336. Is e buidheann carthannais a th’ ann an Oilthigh Dhùn Èideann, clàraichte an Alba, àireamh clàraidh SC005336. EONCKS: Supported by the SA MRC and the New Partnership for Africa’s Development initiative through the Department of Science and Technology of South Africa (#65174). ESO: Supported by the Ministry of Health of the Czech Republic (NU20-04-00393). FBIRN (Function Biomedical Informatics Research Network): Supported by the National Center for Research Resources at the NIH (1 U24 RR021992 (FBIRN) and 1 U24 RR025736-01 (Biomedical Informatics Research Network Coordinating Center; http://www.birncommunity.org)). Data were processed by the UCI High-Performance Computing cluster supported by Joseph Farran (supported by NIMH R01 MH-58262), Harry Mangalam, and Adam Brenner (supported by NIH 5R01 MH61603, 2R01MH058251), and the National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH (through grant UL1 TR000153). FBIRN thank Mrs. Liv McMillan for overall study coordination. FOR2107 Marburg: Funded by the DFG, T.T.J.K. (speaker FOR2107; KI588/14-1, KI588/14-2), Axel Krug (KR3822/5-1, KR3822/7-2), I.N. (NE2254/1-2, NE2254/3-1, NE2254/4-1), Carsten Konrad (KO4291/3-1), and A. Jansen (JA1890/7-1, JA1890/7-2). FOR2107 Münster: Funded by the DFG (FOR2107 DA1151/5-1, DA1151/5-2 to U.D.; SFB-TRR58, Projects C09 and Z02 to U.D.) and the Interdisciplinary Center for Clinical Research of the medical faculty of Münster (Dan3/012/17 to U.D.). Frankfurt: MRI was performed at the Frankfurt Brain Imaging Centre, supported by the DFG and the German Ministry for Education and Research (Brain Imaging Center Frankfurt/Main, DLR01GO0203). GAP (Genetics and Psychosis): The GAP dataset represents independent research funded by the National Institute for Health and Care Research (NIHR) Biomedical Research Centre at South London, Maudsley National Health Service (NHS) Foundation Trust, and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. GIPSI: Supported by “PRISMA U.T” Colciencias Invitación 990 del 3 de Agosto de 2017, Código 111577757629, Contrato 781 de 2017. GROUP: We thank Truda Driesen and Inge Crolla for their coordinating roles in the data collection, as well as the G.R.O.U.P. investigators: R.S.K., Don H. Linszen, Jim van Os, Durk Wiersma, Richard Bruggeman, W.C., L.dH., Lydia Krabbendam, Inez Myin-Germeys. Infrastructure for the GROUP study is funded through the Geestkracht programme of ZonMw (10-000-1001), and matching funds from participating pharmaceutical companies (Lundbeck, AstraZeneca, Eli Lilly, Janssen Cilag) and universities and mental health care organizations (Amsterdam: Academic Psychiatric Centre of the Academic Medical Center and the mental health institutions: GGZ Ingeest, Arkin, Dijk en Duin, GGZ Rivierduinen, Erasmus Medical Centre, GGZ Noord Holland Noord; Groningen: University Medical Center Groningen and the mental health institutions: Lentis, GGZ Friesland, GGZ Drenthe, Dimence, Mediant, GGNet Warnsveld, Yulius Dordrecht and Parnassia psycho-medical center, The Hague; Maastricht: Maastricht University Medical Centre and the mental health institutions: GGzE, GGZ Breburg, GGZ Oost-Brabant, Vincent van Gogh voor Geestelijke Gezondheid, Mondriaan, Virenze riagg, Zuyderland GGZ, MET ggz, Universitair Centrum Sint-Jozef Kortenberg, CAPRI University of Antwerp, PC Ziekeren Sint-Truiden, PZ Sancta Maria Sint-Truiden, GGZ Overpelt, OPZ Rekem; Utrecht: University Medical Center Utrecht and the mental health institutions Altrecht, GGZ Centraal, and Delta). HMS (Homburg Multidiagnosis Study): Sample data collection was supported by a grant of the Competence Network Schizophrenia to O.G. HUBIN (Human Brain Informatics): Supported by the Swedish Research Council (K2015-62X-15077-12-3), 2017-00949, the regional agreement on medical training and clinical research between Stockholm County Council and the Karolinska Institutet, the Knut and Alice Wallenberg Foundation. Huilong: Funded by the National Natural Science Foundation of China (81761128021; 31671145; 81401115; 81401133), Beijing Municipal Science & Technology Commission grant (Z141107002514016), Beijing Natural Science Foundation (7162087), Beijing Municipal Administration of Hospitals Clinical medicine Development of special funding (XMLX201609; zylx201409). IGP: Imaging Genetics in Psychosis study, funded by Project Grants from the NHMRC (APP630471 and APP1081603), and the Macquarie University’s ARC Centre of Excellence in Cognition and its Disorders (CE110001021). This project used participants from the ASRB (see above), using an infrastructure grant from the NSW Ministry of Health. IMH: Supported by research grants from the National Healthcare Group, Singapore (SIG/05004; SIG/05028), and the Singapore Bioimaging Consortium (RP C009/2006) awarded to K.S. KaSP: Supported by the Swedish Research Council (K2015-62X-15077-12-3), and by grants from the Swedish Medical Research Council (2009-7053, 2013-2838, 523-2014-3467), the Swedish Brain Foundation, Åhlén-siftelsen, Svenska Läkaresällskapet, Petrus och Augusta Hedlunds Stiftelse, Torsten Söderbergs Stiftelse, the AstraZeneca-Karolinska Institutet Joint Research Program in Translational Science, Söderbergs Königska Stiftelse, Professor Bror Gadelius Minne, Knut och Alice Wallenbergs stiftelse, the Swedish Federal Government under the LUA/ALF agreement (C.M.S., S. Cervenka), Centre for Psychiatry Research, KID-funding from the Karolinska Institutet. Madrid: Supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), cofinanced by ERDF Funds from the European Commission, “A way of making Europe,” CIBERSAM, Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds, European Union Seventh Framework Program (FP7-4-HEALTH-2009-2.2.1-2-241909—Project EU-GEI, FP7-HEALTH-2013-2.2.1-2-603196—Project PSYSCAN, and FP7-HEALTH-2013-2.2.1-2-602478—Project METSY), European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (115916—Project PRISM, and 777394—Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz. MCIC: Supported by the NIH (NIH/NCRR P41RR14075, R01EB005846 to V.D.C.), the Department of Energy (DE-FG02- 99ER62764), the Mind Research Network, the Morphometry BIRN (1U24, RR021382A), the Function BIRN (U24RR021992-01, NIH.NCRR MO1 RR025758-01, NIMH 1RC1MH089257 to V.D.C.), the DFG (research fellowship to S.E.), and a NARSAD Young Investigator Award (to S.E.). MPRC: Support received from NIH (U01MH108148, 2R01EB015611, R01MH112180, R01DA027680, R01MH085646, P50MH103222, and T32MH067533), a State of Maryland contract (M00B6400091), and NSF grant (1620457). OLIN: Supported by NIH (R01MH106324, R01MH077945). Osaka: Partially supported by AMED (JP21dm0307002, JP21dm0207069, JP21dk0307103, JP21uk1024002, and JP21wm0425012), JSPS KAKENHI (JP20H03611, JP20K06920), and Intramural Research Grant (3-1) for Neurological and Psychiatric Disorders of NCNP. Computations were performed using Research Center for Computational Science, Okazaki, Japan. Oxford: We would like to thank the participants and their families, referring psychiatrists, and the Donnington Health Centre, Oxford. This study is supported by the MRC, OHSRC, UK EPSRC, BBSRC, and Wellcome Trust. PAFIP: We wish to thank all PAFIP research teams and all patients and family members who participated in the study. PAFIP has been funded by Instituto de Salud Carlos III through the projects PI14/00639, PI14/00918, and PI17/01056 (cofunded by ERDF/ESF “Investing in your future”), Health Research Institute Marques de Valdecilla (NTC0235832, NCT02534363), Instituto de Salud Carlos III, FIS 00/3095, 01/3129, PI020499, PI060507, PI10/00183, the SENY Fundació Research Grant (CI 2005‐0308007), the Fundación Marqués de Valdecilla (API07/011), MINECOSAF2013-46292-R, PSYSCAN (Exp.: HEALTH.2013.2.2.1-2_Grant agreement no. 603196). We want to particularly acknowledge the patients and the BioBankValdecilla (PT13/0010/0024) integrated in the Spanish National Biobanks Network for its collaboration. We thank IDIVAL Neuroimaging Unit for its help in the technical execution of this work. RSCZ: Supported in part by the RFBR (20-013-00748). SCORE: This study was supported in part by the SNSF (3232BO_119382). We thank the FePsy (Frueherkennung von Psychosen; early detection of psychosis) Study Group from the University of Basel, Department of Psychiatry, Switzerland, for the recruitment of the study participants. The FePsy Study was supported in part by grant no. SNF 3200-057216/1, ext./2, ext./3. SNUH: Supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) and the Korea Brain Research Institute (KBRI) basic research program through the KBRI, funded by the Ministry of Science, ICT & Future Planning (2019R1C1C1002457, 2020M3E5D9079910, 21-BR-03–01). SWIFT: Supported in part by the SNSF (320030_146789). TOP: Supported by the Research Council of Norway (#160181, 190311, 223273, 213837, 249711), the South-East Norway Health Authority (2014114, 2014097, 2017- 112), the Kristian Gerhard Jebsen Stiftelsen (SKGJ‐MED‐008), and the European Community’s Seventh Framework Programme (FP7/2007–2013), grant agreement no. 602450 (IMAGEMEND). UCISZ: Supported by the NIMH (R21MH097196 to T.G.M.v.E.). Data were processed by the UCI High-Performance Computing cluster (see FBIRN). UMCU: Supported by ZonMw (90802123, 91746370 to H.E.H.P., and 10-000-1001 to R.S.K.). UNIBA: Supported by grant funding from the Italian Ministry of Research (2017M7SZM8_004, PI A.B.; 2017K2NEF4, PI G.P.). UNIMAAS: Supported by ZonMw (91112002) and by a personal grant to T.v.A. (ZonMw-VIDI: 91712394). This clinical trial was registered in the Dutch clinical trial registry under ID: NTR5094 (https://trialsearch.who.int/Trial2.aspx?TrialID=NTR5094). Zurich: Funded by the SNSF., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The association between reasons for first using cannabis, later pattern of use, and risk of first-episode psychosis: the EU-GEI case–control study

  • Spinazzola, Edoardo
  • Quattrone, Diego
  • Rodríguez, Victoria
  • Trotta, Giulia
  • Alameda, Luis
  • Tripoli, Giada
  • Gayer-Anderson, Charlotte
  • Freeman, Tom P.
  • Johnson, Emma C.
  • Jongsma, Hannah E.
  • Stilo, Simona
  • La Cascia, Caterina
  • Ferraro, Laura
  • La Barbera, Daniele
  • Lasalvia, Antonio
  • Tosato, Sarah
  • Tarricone, Ilaria
  • D'Andrea, Giuseppe
  • Galatolo, Michela
  • Tortelli, Andrea
  • Tagliabue, Ilaria
  • Turco, Marco
  • Pompili, Maurizio
  • Selten, Jean-Paul
  • Haan, Lieuwe de
  • Menezes, Paulo Rossi
  • Del-Ben, Cristina M.
  • Santos, José Luis
  • Arrojo, Manuel
  • Bobes, Julio
  • Sanjuán, Julio
  • Bernardo, Miguel
  • Arango, Celso
  • Kirkbride, James B.
  • Jones, Peter B.
  • O'Donovan, Michael C.
  • Rutten, Bart P. F.
  • Os, Jim van
  • Morgan, Craig
  • Sham, Pak C.
  • Austin-Zimmerman, Isabelle
  • Li, Zhikun
  • Vassos, Evangelos
  • Murray, Robin M.
  • Forti, Marta Di
  • EU-GEI WP2 Group
© The Author(s), 2023. Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited., [Background] While cannabis use is a well-established risk factor for psychosis, little is known about any association between reasons for first using cannabis (RFUC) and later patterns of use and risk of psychosis., [Methods] We used data from 11 sites of the multicentre European Gene-Environment Interaction (EU-GEI) case–control study. 558 first-episode psychosis patients (FEPp) and 567 population controls who had used cannabis and reported their RFUC. We ran logistic regressions to examine whether RFUC were associated with first-episode psychosis (FEP) case–control status. Path analysis then examined the relationship between RFUC, subsequent patterns of cannabis use, and case–control status., [Results] Controls (86.1%) and FEPp (75.63%) were most likely to report ‘because of friends’ as their most common RFUC. However, 20.1% of FEPp compared to 5.8% of controls reported: ‘to feel better’ as their RFUC (χ2 = 50.97; p < 0.001). RFUC ‘to feel better’ was associated with being a FEPp (OR 1.74; 95% CI 1.03–2.95) while RFUC ‘with friends’ was associated with being a control (OR 0.56; 95% CI 0.37–0.83). The path model indicated an association between RFUC ‘to feel better’ with heavy cannabis use and with FEPp-control status., [Conclusions] Both FEPp and controls usually started using cannabis with their friends, but more patients than controls had begun to use ‘to feel better’. People who reported their reason for first using cannabis to ‘feel better’ were more likely to progress to heavy use and develop a psychotic disorder than those reporting ‘because of friends’., This study was funded by the Medical Research Council, the European Community's Seventh Framework Program grant (agreement HEALTH-F2-2009-241909 (Project EU-GEI), Sao Paulo Research Foundation (grant 2012/0417-0), the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust and King's College London, the NIHR BRC at University College London, and the Wellcome Trust (grant 101272/Z/12/Z). ES was supported by Lord Leverhulme's Charitable Trust and the Velvet Foundation and by the Medical Research Council (MRC) – UKRI [MR/T007818/1]. MDF and GT are supported by the Medical Research Council (MRC) – UKRI [MR/T007818/1]. DQ is supported by MRC/UKRI CARP (MRC CARP grant MR/W030608/1). Dr Kirkbride is supported by the National Institute for Health Research (NIHR) University College London (UCL) Biomedical Research Centre (BRC). Dr Emma Johnson receives funding from NIDA: K01DA051759., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The relationship between genetic liability, childhood maltreatment, and IQ: findings from the EU-GEI multicentric case–control study

  • Sideli, Lucia
  • Aas, Monica
  • Quattrone, Diego
  • La Barbera, Daniele
  • La Cascia, Caterina
  • Ferraro, Laura
  • Alameda, Luis
  • Velthorst, Eva
  • Trotta, Giulia
  • Tripoli, Giada
  • Schimmenti, Adriano
  • Fontana, Andrea
  • Gayer-Anderson, Charlotte
  • Stilo, Simona
  • Seminerio, Fabio
  • Sartorio, Crocettarachele
  • Marrazzo, Giovanna
  • Lasalvia, Antonio
  • Tosato, Sarah
  • Tarricone, Ilaria
  • Berardi, Domenico
  • D’Andrea, Giuseppe
  • EU-GEI WP2 Group
  • Arango, Celso
  • Arrojo, Manuel
  • Bernardo, Miguel
  • Bobes, Julio
  • Sanjuán, Julio
  • Santos, José Luis
  • Rossi Menezes, Paulo
  • Del-Ben, Cristina Marta
  • Jongsma, Hannah E.
  • Jones, Peter B.
  • Kirkbride, James B.
  • Llorca, Pierre-Michel
  • Tortelli, Andrea
  • Pignon, Baptiste
  • Haan, Lieuwe de
  • Selten, Jean-Paul
  • Os, Jim van
  • Rutten, Bart P. F.
  • Bentall, Richard
  • Di Forti, Marta
  • Murray, Robin M.
  • Morgan, Craig
  • Fisher, Helen L.
© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/., This study investigated if the association between childhood maltreatment and cognition among psychosis patients and community controls was partially accounted for by genetic liability for psychosis. Patients with first-episode psychosis (N = 755) and unaffected controls (N = 1219) from the EU-GEI study were assessed for childhood maltreatment, intelligence quotient (IQ), family history of psychosis (FH), and polygenic risk score for schizophrenia (SZ-PRS). Controlling for FH and SZ-PRS did not attenuate the association between childhood maltreatment and IQ in cases or controls. Findings suggest that these expressions of genetic liability cannot account for the lower levels of cognition found among adults maltreated in childhood., We are grateful to the EU-GEI study participants for their essential contribution to this project. The EU-GEI Study is funded by grant agreement HEALTH-F2-2010–241909 (Project EU-GEI) from the European Community’s Seventh Framework Programme, and Grant 2012/0417–0 from the São Paulo Research Foundation. B.P.F. Rutten is funded by a VIDI award (no. 91.718.336) from the Netherlands Scientific Organization. H. L. Fisher, C. Gayer-Anderson, and C. Morgan are supported by the Economic and Social Research Council (ESRC) Centre for Society and Mental Health at King’s College London [ES/S012567/1]. D. Quattrone is supported by the Medical Research Council Clinical Academic Research Partnership [MR/W030608/1]. M. Aas is supported by an MRC fellowship (#MR/WO27720/1). C. Arango has received support from the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), co-financed by the European Union, ERDF Funds from the European Commission, “A way of making Europe”, financed by the European Union—NextGenerationEU (PMP21/00051, PI19/01024), CIBERSAM, Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds, European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (Grant agreement No.101034377), Project AIMS-2-TRIALS (Grant agreement No 777394), Horizon Europe, the National Institute of Mental Health of the National Institutes of Health under Award Number 1U01MH124639-01 (Project ProNET) and Award Number 5P50MH115846-03 (Project FEP-CAUSAL), Fundación Familia Alonso, and Fundación Alicia Koplowitz. The views expressed are those of the authors and not necessarily those of the ESRC or King’s College London., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Accelerated Cortical Thinning in Schizophrenia Is Associated With Rare and Common Predisposing Variation to Schizophrenia and Neurodevelopmental Disorders

  • González-Peñas, Javier
  • Alloza, Clara
  • Brouwer, Rachel
  • Díaz-Caneja, Covadonga M.
  • Costas, Javier
  • González-Lois, Noemí
  • Gallego, Ana Guil
  • Hoyos, Lucía de
  • Gurriarán, Xaquín
  • Andreu-Bernabeu, Álvaro
  • Romero-García, Rafael
  • Fañanás, Lourdes
  • Bobes, Julio
  • González-Pinto, Ana
  • Crespo-Facorro, Benedicto
  • Martorell, Lourdes
  • Arrojo, Manuel
  • Vilella, Elisabet
  • Gutiérrez-Zotes, Alfonso
  • Perez-Rando, Marta
  • Moltó, María Dolores
  • Buimer, Elizabeth
  • van Haren, Neeltje
  • Cahn, Wiepke
  • O'Donovan, Michael
  • Kahn, René S
  • Arango, Celso
  • Pol, Hilleke Hulshoff
  • Janssen, Joost
  • Schnack, Hugo
Schizophrenia is a highly heritable disorder characterized by increased cortical thinning throughout the life span. Studies have reported a shared genetic basis between schizophrenia and cortical thickness. However, no genes whose expression is related to abnormal cortical thinning in schizophrenia have been identified., This work was supported by Spanish Ministry of Science, Innovation and Universities Instituto de Salud Carlos III (Grant Nos. SAM16PE07CP1, PI16/02012, PI17/00997, PI19/01024, and PI20/00721), cofinanced by European Regional Development Funds from the European Commission, “A way of making Europe,” CIBERSAM (Centro de Investigación Biomédica en Red de Salud Menta); Madrid Regional Government (Grant No. B2017/BMD-3740 AGES-CM-2), European Union Structural Funds; the European Union Seventh Framework Program (Grant Nos. FP7-4-HEALTH-2009-2.2.1-2-241909 [Project EU-GEI], FP7- HEALTH-2013-2.2.1-2-603196 [Project PSYSCAN], and FP7-HEALTH-2013-2.2.1-2-602478 [Project METSY]); and the European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (Grant No. 115916, Project PRISM, and Grant No. 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz, and Fundación Mutua Madrileña. CMD-C holds a Juan Rodés Grant from Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (Grant No. JR19/00024). JG-P held a Sara Borrell grant during the development of the research from Instituto de Salud Carlos III (Grant No. CD20/00118)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study

  • Rodríguez, Victoria
  • Alameda, Luis
  • Quattrone, Diego
  • Tripoli, Giada
  • Gayer-Anderson, Charlotte
  • Spinazzola, Edoardo
  • Trotta, Giulia
  • Jongsma, Hannah E
  • Stilo, Simona
  • La Cascia, Caterina
  • Ferraro, Laura
  • La Barbera, Daniele
  • Lasalvia, Antonio
  • Tosato, Sarah
  • Tarricone, Ilaria
  • Bonora, Elena
  • Jamain, Stéphane
  • Selten, Jean-Paul
  • Velthorst, Eva
  • de Haan, Lieuwe
  • Llorca, Pierre-Michel
  • Arrojo, Manuel
  • Bobes, Julio
  • Bernardo, Miguel
  • Arango, Celso
  • Kirkbride, James
  • Jones, Peter B
  • Rutten, Bart P
  • Richards, Alexander
  • Sham, Pak C
  • O'Donovan, Michael
  • Van Os, Jim
  • Morgan, Craig
  • Di Forti, Marta
  • Murray, Robin M
  • Vassos, Evangelos
Schizophrenia (SZ), bipolar disorder (BD) and depression (D) run in families. This susceptibility is partly due to hundreds or thousands of common genetic variants, each conferring a fractional risk. The cumulative effects of the associated variants can be summarised as a polygenic risk score (PRS). Using data from the EUropean Network of national schizophrenia networks studying Gene-Environment Interactions (EU-GEI) first episode case-control study, we aimed to test whether PRSs for three major psychiatric disorders (SZ, BD, D) and for intelligent quotient (IQ) as a neurodevelopmental proxy, can discriminate affective psychosis (AP) from schizophrenia-spectrum disorder (SSD)., This work was supported by funding from the European Community's Seventh Framework Programme under grant agreement No. HEALTH-F2-2010-241909 (Project EU-GEI). VR was funded by a PhD scholarship supported by Lord Leverhulme's Charitable Trust and the Velvet Foundation. EV is funded by the National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. CA was supported by the Spanish Ministry of Science and Innovation; Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by ERDF Funds from the European Commission, ‘A way of making Europe’, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), Fundación Familia Alonso and Fundación Alicia Koplowitz. MB was supported by the Ministry od Economy and Competitivity (PI08/0208; PI11/00325; PI14/00612), Instituto de Salud Carlos III – ERDF Funds from the European Commission, ‘A way of making Europe’, CIBERSAM, by the CERCA Programme/Generalitat de Catalunya and Secretaria d'Universitats i Recerca del Departament d'Economia I Coneixement (2017SGR1355). Departament de Salut de la Generalitat de Catalunya, en la convocatoria corresponent a l'any 2017 de concessió de subvencions del PERIS 2016-2020, modalitat Projectes de recerca orientats a l'atenció primària, amb el codi d'expedient SLT006/17/00345; and grateful for the support of the Institut de Neurociències, Universitat de Barcelona., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Effects of copy number variations on brain structure and risk for psychiatric illness: Large-scale studies from the ENIGMA working groups on CNVs

  • Sønderby, Ida E.
  • Ching, Christopher R. K.
  • Thomopoulos, Sophia I.
  • Meer, Dennis van der
  • Sun, Daqiang
  • Villalón-Reina, Julio E.
  • Agartz, Ingrid
  • Amunts, Katrin
  • Arango, Celso
  • Armstrong, Nicola J.
  • Ayesa-Arriola, Rosa
  • Bakker, Geor
  • Bassett, Anne S.
  • Boomsma, Dorret I.
  • Bülow, Robin
  • Butcher, Nancy J.
  • Calhoun, Vince D.
  • Caspers, Svenja
  • Chow, Eva W C
  • Cichon, Sven
  • Ciufolini, Simone
  • Craig, Michael C.
  • Crespo-Facorro, Benedicto
  • Cunningham, Adam C.
  • Dale, Anders M.
  • Dazzan, Paola
  • de Zubicaray, Greig I.
  • Djurovic, Srdjan
  • Doherty, Joanne L.
  • Donohoe, Gary
  • Draganski, Bogdan
  • Durdle, Courtney A.
  • Ehrlich, Stefan
  • Emanuel, Beverly S.
  • Espeseth, Thomas
  • Fisher, Simon E.
  • Ge, Tian
  • Glahn, David C.
  • Grabe, Hans J.
  • Gur, Raquel E.
  • Gutman, Boris A.
  • Haavik, Jan
  • Håberg, Asta K.
  • Hansen, Laura A.
  • Hashimoto, Ryota
  • Hibar, Derrek P.
  • Holmes, Avram J.
  • Hottenga, Jouke-Jan
  • Hulshoff Pol, Hilleke E
  • Jalbrzikowski, Maria
  • Knowles, Emma E. M.
  • Kushan, Leila
  • Linden, David E J.
  • Liu, Jingyu
  • Lundervold, Astri J.
  • Martin-Brevet, Sandra
  • Martínez, Kenia
  • Mather, Karen A.
  • Mathias, Samuel R.
  • McDonald-McGinn, Donna M.
  • McRae, Allan F.
  • Medland, Sarah E.
  • Moberget, Torgeir
  • Modenato, Claudia
  • Monereo Sánchez, Jennifer
  • Moreau, Clara A.
  • Mühleisen, Thomas W.
  • Paus, Tomas
  • Pausova, Zdenka
  • Prieto, Carlos
  • Ragothaman, Anjanibhargavi
  • Reinbold, Céline S.
  • Reis Marques, Tiago
  • Repetto, Gabriela M.
  • Reymond, Alexandre
  • Roalf, David R.
  • Rodriguez-Herreros, Borja
  • Rucker, James J.
  • Sachdev, Perminder S.
  • Schmitt, James E.
  • Schofield, Peter R.
  • Silva, Ana I.
  • Stefansson, Hreinn
  • Stein, Dan J.
  • Tamnes, Christian K.
  • Tordesillas-Gutiérrez, Diana
  • Ulfarsson, Magnus O.
  • Vajdi, Ariana
  • van 't Ent, Dennis
  • Bree, Marianne B. M. van den
  • Vassos, Evangelos
  • Vázquez-Bourgon, Javier
  • Vila-Rodriguez, Fidel
  • Walters, G Bragi
  • Wen, Wei
  • Westlye, Lars T.
  • Wittfeld, Katharina
  • Zackai, Elaine H.
  • Stefánsson, Kári
  • Jacquemont, Sebastien
  • Thompson, Paul M.
  • Bearden, Carrie E.
  • Andreassen, Ole A.
  • ENIGMA-CNV Working Group
  • ENIGMA 22q11.2 Deletion Syndrome Additional
Data sharing is not applicable to this article as no new data were created or analyzed in this study., ENIGMA-CNV Additional Members: Manon Bernard, Bloorview Research Institute, Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada. Nicholas B. Blackburn, Department of Human Genetics, School of Medicine, University of Texas Rio Grande Valley, Brownsville, Texas, USA; South Texas Diabetes and Obesity Institute, School of Medicine, University of Texas Rio Grande Valley, Brownsville, Texas, USA. Rune Bøen, Department of Medical Genetics, Oslo University Hospital, Oslo, Norway; Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Oslo University Hospital and University of Oslo, Oslo, Norway. Eco de Geus, Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; Amsterdam Public Health (APH) Research Institute, Amsterdam UMC, Amsterdam, The Netherlands. Sonja M. C. de Zwarte, Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. Marta Di Forti, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. Oleksandr Frei, Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health; Addiction, Oslo University Hospital and University of Oslo, Oslo, Norway and Center for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway, Vincent Frouin, Université Paris-Saclay, CEA, Neurospin, Gif-sur-Yvette, France. Masaki Fukunaga, Division of Cerebral Integration, National Institute for Physiological Sciences, Okazaki, Japan. Jayne Y. Hehir-Kwa, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Manon H. J. Hillegers, Department of Child and Adolescent Psychiatry/Psychology, Erasmus Medical Center, Rotterdam, The Netherlands. Per Hoffmann, Institute of Human Genetics, University of Bonn, Bonn, Germany; Human Genomics Research Group, Department of Biomedicine, University of Basel, Basel, Switzerland. Georg Homuth, Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany. Neda Jahanshad, Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, CA, USA. Sanne Koops, Department of Biomedical Sciences of Cells & Systems, Cognitive Neurosciences, University of Groningen, University Medical Center Groningen (UMCG), Groningen, The Netherlands. Kuldeep Kumar, Sainte Justine Research Center, University of Montreal, Montreal, QC, Canada. Masataka Kikuchi, Graduate School of Medicine, Osaka University, Osaka, Japan. Stephanie Le Hellard, NORMENT, Department of Clinical Science, University of Bergen, Bergen, Norway; Dr. Einar Martens Research Group for Biological Psychiatry, Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway. Costin Leu, Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK; Stanley Center for Psychiatric Research, Broad Institute of Harvard and M.I.T, Cambridge, MA, USA. Robin M Murray, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. Terje Nærland, KG Jebsen Centre for Neurodevelopmental Disorders, University of Oslo, Oslo, Norway; NevSom, Department of Rare Disorders, Oslo University Hospital, Oslo, Norway. Lars Nyberg, Integrative Medical Biology (IMB) Umeå University, Umeå, Sweden; Department of Psychiatry, Erasmus University Medical Center, Rotterdam, The Netherlands. Roel A. Ophoff, Center for Neurobehavioral Genetics, University of California Los Angeles, Los Angeles, CA, USA; Department of Psychiatry, Erasmus University Medical Center, Rotterdam, The Netherlands. G Bruce Pike, Radiology and Clinical Neurosciences, University of Calgary, Calgary, AB, Canada. Sigrid B. Sando, Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway; Department of Neurology and Clinical Neurophysiology, University Hospital of Trondheim, Trondheim, Norway. Jean Shin, The Hospital for Sick Children, Toronto, ON, Canada; Departments of Physiology and Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada. Elena Shumskaya, Donders Institute for Brain, Cognition, and Behavior, Nijmegen, The Netherlands. Sanjay M. Sisodiya, Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK; Chalfont Centre for Epilepsy, Chalfont-St-Peter, Bucks, UK. Vidar M. Steen, NORMENT, Department of Clinical Science, University of Bergen, Bergen, Norway; Dr. Einar Martens Research Group for Biological Psychiatry, Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway. Alexander Teumer, Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany, Anne Uhlmann, Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa. Margaret J. Wright, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia, ENIGMA 22q11.2 Deletion Syndrome Additional Members: Kevin M. Antshel, Department of Psychology, Syracuse University, Syracuse, NY, USA. Linda E. Campbell, University of Newcastle, Newcastle, NSW, Australia. Nicolas A. Crossley, Department of Psychiatry, Pontificia Universidad Católica de Chile, Santiago, Chile. T. Blaine Crowley, Division of Human Genetics and 22q and You Center, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Eileen Daly, Department of Forensic and Neurodevelopmental Sciences, and the Sackler Institute for Translational Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK. Ania M. Fiksinski, Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, ON, Canada; Dalglish Family 22q Clinic for Adults with 22q11.2 Deletion Syndrome, Toronto General Hospital, University Health Network, Toronto, ON, Canada; Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. Jennifer K. Forsyth, Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles, CA, USA. Wanda Fremont, Department of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, Syracuse, NY, USA. Naomi J. Goodrich-Hunsaker, MIND Institute and Department of Psychiatry and Behavioral Sciences, University of California Davis, Davis, CA, USA; Department of Neurology, University of Utah, Salt Lake City, UT, USA. Maria Gudbrandsen, Department of Forensic and Neurodevelopmental Sciences, and the Sackler Institute for Translational Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK. Rachel K. Jonas, Semel Institute for Neuroscience and Human Behavior, Departments of Psychiatry and Biobehavioral Sciences and Psychology, University of California Los Angeles, Los Angeles, CA, USA. Wendy R. Kates, Department of Psychiatry and Behavioral Sciences, State University of New York at Upstate Medical University, Syracuse, NY, USA. Amy Lin, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, CA, USA. Kathryn L. McCabe, Department of Psychiatry and Behavioral Sciences, State University of New York at Upstate Medical University, Syracuse, NY, USA; Department of Psychology, University of Newcastle, Newcastle, NSW, Australia. Hayley Moss, MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK. Declan G. Murphy, Department of Forensic and Neurodevelopmental Sciences, and the Sackler Institute for Translational Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK; Behavioural Genetics Clinic, Adult Autism Service, Behavioural and Developmental Psychiatry Clinical Academic Group, South London and Maudsley NHS Foundation Trust, London, UK. Kieran C. Murphy, Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland. Michael J. Owen, MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK. Kosha Ruparel, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. Tony. J. Simon, MIND Institute and Department of Psychiatry and Behavioral Sciences, University of California Davis, Davis, CA, USA. Therese van Amelsvoort, Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands. Jacob A. S. Vorstman, Department of Psychiatry, The Hospital for Sick Children, Toronto, ON, Canada., The Enhancing NeuroImaging Genetics through Meta-Analysis copy number variant (ENIGMA-CNV) and 22q11.2 Deletion Syndrome Working Groups (22q-ENIGMA WGs) were created to gain insight into the involvement of genetic factors in human brain development and related cognitive, psychiatric and behavioral manifestations. To that end, the ENIGMA-CNV WG has collated CNV and magnetic resonance imaging (MRI) data from ~49,000 individuals across 38 global research sites, yielding one of the largest studies to date on the effects of CNVs on brain structures in the general population. The 22q-ENIGMA WG includes 12 international research centers that assessed over 533 individuals with a confirmed 22q11.2 deletion syndrome, 40 with 22q11.2 duplications, and 333 typically developing controls, creating the largest-ever 22q11.2 CNV neuroimaging data set. In this review, we outline the ENIGMA infrastructure and procedures for multi-site analysis of CNVs and MRI data. So far, ENIGMA has identified effects of the 22q11.2, 16p11.2 distal, 15q11.2, and 1q21.1 distal CNVs on subcortical and cortical brain structures. Each CNV is associated with differences in cognitive, neurodevelopmental and neuropsychiatric traits, with characteristic patterns of brain structural abnormalities. Evidence of gene-dosage effects on distinct brain regions also emerged, providing further insight into genotype–phenotype relationships. Taken together, these results offer a more comprehensive picture of molecular mechanisms involved in typical and atypical brain development. This “genotype-first” approach also contributes to our understanding of the etiopathogenesis of brain disorders. Finally, we outline future directions to better understand effects of CNVs on brain structure and behavior., The ENIGMA Consortium is supported by the NIH Big Data to Knowledge (BD2K) program under consortium grant number U54 EB020403 (PI: Thompson). OAA is supported by the Research Council of Norway, South East Norway Health Authority, KG Jebsen Stiftelsen, EU H2020. C. A. has been funded by the Spanish Ministry of Science and Innovation; Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM; Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds; European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241,909 (Project EU-GEI), FP7- HEALTH-2013-2.2.1-2-603,196 (Project PSYSCAN) and FP7- HEALTH-2013-2.2.1-2-602,478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative two Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso and Fundación Alicia Koplowitz. R. A-A is funded by a Miguel Servet contract from the Carlos III Health Institute (CP18/00003). G. B. is supported by the Dutch Organization for Health Research and Development ZonMw (grants 91112002 & 91712394). A. S. B. is supported by the Dalglish Family Chair in 22q11.2 Deletion Syndrome, Canadian Institutes of Health Research (CIHR) grants MOP-79518, MOP-89066, MOP-97800 and MOP-111238, and NIMH grant number U01 MH101723–01(3/5). C. E. B. is also supported by the National Institute of Mental Health: RO1 MH085953, R01 MH100900 and 1U01MH119736. N. E. B. is granted the KNAW Academy Professor Award (PAH/6635). V. D. C. is supported by NIH R01 MH094524. S. C. is supported by the European Union's Horizon 2020 Framework Programme for Research and Innovation under the Specific Grant Agreement No. 945539 (Human Brain Project SGA3); Helmholtz Initiative and Networking Fund. C. R. K. C. is supported by NIA T32AG058507. E. W. C. C. is supported by the Canadian Institutes of Health Research, Ontario Mental Health Foundation grant MOP-74631 and NIMH grant U01MH101723–01(3/5). S. Ci. has received funding from the European Union's Horizon 2020 Framework Programme for Research and Innovation under the Specific Grant Agreement No. 945539 (Human Brain Project SGA3). M. C. C. is supported by the Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. N. A. C. is supported by Agencia Nacional de Investigación y Desarrollo (ANID Chile) PIA ACT192064. GId. Z. is supported by the NHMRC. J. L. D. and D. E. J. L. are supported by the Wellcome Trust. T. B. C. is supported by NICHD grant PO1-HD070454, NIH grant UO1-MH191719, and NIMH grant R01 MH087636-01A1. AMD is supported by U24DA041147. B. D. is supported by the Swiss National Science Foundation (NCCR Synapsy, project grant numbers 32003B_135679, 32003B_159780, 324730_192755 and CRSK-3_190185), the Leenaards Foundation and the Roger De Spoelberch Foundation. SE is supported by the NARSAD-Young Investigator Grant “Epigenetic Regulation of Intermediate Phenotypes in Schizophrenia”. B. E. S. is supported by the NIH (NIMH). D. C. G. is supported by NIH grant numbers MH078143, MH083824, AG058464. W. R. K. is supported by NIH/MH R0106824. R. E. G. is supported by NIH/NIMH grant numbers MH087626, MH119737. DMMcD-McG is supported by National Institutes of Mental Health (NIMH), grant numbers MH119737-02; MH191719; and MH087636-01A1. S. E. M. is supported by NHMRC grants APP1103623; APP1158127; APP1172917. TM is supported by Research Council of Norway - grant number 273345. D. G. M. is supported by the National Institute for Health Research Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London and EU-AIMS (European Autism Interventions)/EU AIMS-2-TRIALS, a European Innovative Medicines Initiative Joint Undertaking under grant agreements 115300 and 777394. T. N. was supported by Stiftelsen KG Jebsen under grant number SKGJ-MED-021. R. A. O. is supported by NIMH R01 MH090553. S. Y. S. has been funded by the Canadain Institutes of Health Research. M. J. O. is supported by MRC Centre grant MR/L010305/1 and Wellcome Trust grant 100,202/Z/12/Z; Dr. Owen has received research support from Takeda. Z. P. is supported by CIHR, CFI, HSFC. B. G. P. is supported by CIHR FDN 143290 and CAIP Chair. G. M. R. is supported by Fondecyt-Chile #1171014 and ANID-Chile ACT192064. A. Re. was supported by a grant from the Swiss National Science Foundation (31003A_182632). DRR is supported by R01 MH120174 (PI: Roalf). This report represents independent research funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London (to J. J. R). PSS is supported by NHMRC (Australia) program grant 1093083. J. E. S. is supported by NIH K01-ES026840. S. M. S. is supported by the Epilepsy Society. T. J. S. is supported by NIH grants R01MH107108, R01HD042794, and HDU54079125. I. E. S. is supported by South-Eastern Norway Regional Health Authority (#2020060), European Union's Horizon2020 Research and Innovation Programme (CoMorMent project; grant #847776) and the KG Jebsen Foundation (SKGJ-MED-021). V. M. S. is supported by Research Council of Norway (CoE funding scheme, grant number 223273). D. J. S. is supported by the SA MRC. C. K. T. is supported by Research Council of Norway (#230345, #288083, #223273) and South-Eastern Norway Regional Health Authority (#2019069, #2021070, #500189). D. T.-G. was supported by the Instituto de Salud Carlos III (PI14/00639 and PI14/00918) and Fundación Instituto de Investigación Marqués de Valdecilla (NCT0235832 and NCT02534363). Dvd. M. is supported by Research Council of Norway #276082. F. V. R. is supported by the Michael Smith Foundation for Health Research Scholar Award. deCODE genetics has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreements' no. 115008 (NEWMEDS) and no. 115300 (EUAIMS), of which resources are composed of EFPIA in-kind contribution and financial contribution from the European Union's Seventh Framework Programme (EU-FP7/2007–2013). L. T. W. is supported by Research Council of Norway, European Research Council. The IDIVAL neuroimage unit is supported by Instituto de Salud Carlos III PI020499, research funding SCIII-INT13/0014, MICINN research funding SAF2010-20840-C02-02, SAF2013-46292-R. The TOP/NORMENT study are supported by the Research Council of Norway (#223273). The GOBS study data collection was supported in part by the National Institutes of Health (NIH) grants: R01 MH078143, R01 MH078111, and R01 MH083824 with work conducted in part in facilities constructed under the support of NIH grant number C06 RR020547. The Sydney Memory and Ageing Study has been funded by three National Health & Medical Research Council (NHMRC) Program Grants (ID No. ID350833, ID568969, and APP1093083). We thank the participants and their informants for their time and generosity in contributing to this research. We also acknowledge the MAS research team: https://cheba.unsw.edu.au/research-projects/sydney-memory-and-ageing-study. We acknowledge the contribution of the OATS research team (https://cheba.unsw.edu.au/project/older-australian-twins-study) to this study. The OATS study has been funded by a National Health & Medical Research Council (NHMRC) and Australian Research Council (ARC) Strategic Award Grant of the Aging Well, Aging Productively Program (ID No. 401162); NHMRC Project (seed) Grants (ID No. 1024224 and 1025243); NHMRC Project Grants (ID No. 1045325 and 1085606); and NHMRC Program Grants (ID No. 568969 and 1093083). We thank the participants for their time and generosity in contributing to this research. This research was facilitated through access to Twins Research Australia, a national resource supported by a Centre of Research Excellence Grant (ID No. 1079102) from the National Health and Medical Research Council. The NCNG sample collection was supported by grants from the Bergen Research Foundation and the University of Bergen, the Dr Einar Martens Fund, the KG Jebsen Foundation, the Research Council of Norway, to S. L. H., V. M. S., A. J. L., and T. E. The authors thank Dr. Eike Wehling for recruiting participants in Bergen, and Professor Jonn-Terje Geitung and Haraldplass Deaconess Hospital for access to the MRI facility. Additional support by RCN grants 177458/V50 and 231286/F20. The Betula study was supported by a Wallenberg Scholar Grant (KAW). The HUNT Study is a collaboration between HUNT Research Centre (Faculty of Medicine and Health Sciences, NTNU—Norwegian University of Science and Technology), Nord-Trøndelag County Council, Central Norway Health Authority, and the Norwegian Institute of Public Health. HUNT-MRI was funded by the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology, and the Norwegian National Advisory Unit for functional MRI. Research for the GAP cohort was supported by the Department of Health via the National Institute for Health Research (NIHR) Specialist Biomedical Research Center for Mental Health award to South London and Maudsley NHS Foundation Trust (SLaM) and the Institute of Psychiatry at King's College London, London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. S.J. is supported by Calcul Quebec (http://www.calculquebec.ca), Compute Canada (http://www.computecanada.ca), the Brain Canada Multi investigator research initiative (MIRI), the Institute of Data Valorization (Canada First Research Excellence Fund), CHIR, Canada Research Chairs and the Jeanne et Jean Louis Levesque Foundation. The NTR cohort was supported by the Netherlands Organization for Scientific Research (NWO), MW904-61-193 (de Geus & Boomsma), MaGWnr: 400-07-080 (van 't Ent), MagW 480-04-004 (Boomsma), NWO/SPI 56-464-14,192 (Boomsma), the European Research Council, ERC-230374 (Boomsma), and Amsterdam Neuroscience. Funding for genotyping was obtained from the National Institutes of Health (NIMH U24 MH068457-06; Grand Opportunity grants 1RC2 MH089951, and 1RC2 MH089995); the Avera Institute for Human Genetics, Sioux Falls, South Dakota (USA). Part of the genotyping and analyses were funded by the Genetic Association Information Network (GAIN) of the Foundation for the National Institutes of Health. The Brainscale study was supported by the Netherlands Organization for Scientific Research MagW 480-04-004 (Boomsma), 51.02.060 (Hilleke Hulshoff Pol), 668.772 (Boomsma & Hulshoff Pol); NWO/SPI 56-464-14192 (Boomsma), the European Research Council (ERC230374) (Boomsma), High Potential Grant Utrecht University (Hulshoff Pol), NWO Brain and Cognition 433-09-220 (Hulshoff Pol). SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs and the Social Ministry of the Federal State of Mecklenburg-West Pomerania. Genome-wide SNP typing in SHIP and MRI scans in SHIP and SHIP-TREND have been supported by a joint grant from Siemens Healthcare, Erlangen, Germany and the Federal State of Mecklenburg-West Pomerania. The ENIGMA-22q11.2 Deletion Syndrome Working Group wishes to acknowledge our dear colleague Dr. Clodagh Murphy, who sadly passed away in April 2020. Open access funding enabled and organized by Projekt DEAL., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Opposite cannabis-cognition associations in psychotic patients depending on family history

  • González-Pinto, A.
  • González-Ortega, I.
  • Alberich, S.
  • De Azúa, S.R.
  • Bernardo, M.
  • Bioque, M.
  • Cabrera, B.
  • Corripio, I.
  • Arango, C.
  • Lobo, A.
  • Sánchez-Torres, A.M.
  • Cuesta, M.J.
  • Ugarte, A.
  • Fernández, M.
  • Mezquida, G.
  • Meseguer, A.
  • Vieta, E.
  • Torrent, C.
  • Contreras, F.
  • Albacete, A.
  • Alonso-Solís, A.
  • Rabella, M.
  • Moreno-Izco, L.
  • Usall, J.
  • Butjosa, A.
  • Ibáñez, Á.
  • Bobes, J.
  • Al-Halabí, S.
  • Zapata-Usábel, M.T.
  • Laporta-Herrero, I.
  • Balanzá-Martínez, V.
  • Bergé, D.
  • Mané, A.
  • Rodriguez-Jimenez, R.
  • Morales-Muñoz, I.
  • Gutierrez, M.
  • Zabala, A.
  • Sarró, S.
  • Landin-Romero, R.
  • Serna, De La
  • Baeza, I.
  • Parellada, M.
  • Espliego, A.
  • Juan, J.S.
  • Aguilar, E.
The objective of this study is to investigate cognitive performance in a first-episode psychosis sample, when stratifying the interaction by cannabis use and familial or non-familial psychosis. Hierarchical-regression models were used to analyse this association in a sample of 268 first-episode psychosis patients and 237 controls. We found that cannabis use was associated with worse working memory, regardless of family history. However, cannabis use was clearly associated with worse cognitive performance in patients with no family history of psychosis, in cognitive domains including verbal memory, executive function and global cognitive index, whereas cannabis users with a family history of psychosis performed better in these domains. The main finding of the study is that there is an interaction between cannabis use and a family history of psychosis in the areas of verbal memory, executive function and global cognition: that is, cannabis use is associated with a better performance in patients with a family history of psychosis and a worse performance in those with no family history of psychosis. In order to confirm this hypothesis, future research should explore the actual expression of the endocannabinoid system in patients with and without a family history of psychosis.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Development of Proteomic Prediction Models for Transition to Psychotic Disorder in the Clinical High-Risk State and Psychotic Experiences in Adolescence.

  • Mongan, D.
  • Föcking, M.
  • Healy, C.
  • Susai, S. R.
  • Heurich, M.
  • Wynne, K.
  • Nelson, B.
  • McGorry, P. D.
  • Amminger, G. P.
  • Nordentoft, M.
  • Krebs, M. O.
  • Riecher-Rössler, A.
  • Bressan, R A.
  • Barrantes Vidal, Neus
  • Borgwardt, S.
  • Ruhrmann, S.
  • Sachs, S.
  • Pantelis, Christos
  • Van der Gaag, Mark
  • de Haan, L.
  • Valmaggia, L.
  • Pollak, T. A.
  • Kempton, Matthew J.
  • Rutten, B. P. F.
  • Whelan, R.
  • Cannon, M.
  • Zammit, S.
  • Cagney, G.
  • Cotter, D. R.
  • McGuire, P. for the European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI).
  • Rosa de la Cruz, Araceli
Importance: Biomarkers that are predictive of outcomes in individuals at risk of psychosis would facilitate individualized prognosis and stratification strategies. Objective: To investigate whether proteomic biomarkers may aid prediction of transition to psychotic disorder in the clinical high-risk (CHR) state and adolescent psychotic experiences (PEs) in the general population. Design, Setting, and Participants: This diagnostic study comprised 2 case-control studies nested within the European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) and the Avon Longitudinal Study of Parents and Children (ALSPAC). EU-GEI is an international multisite prospective study of participants at CHR referred from local mental health services. ALSPAC is a United Kingdom-based general population birth cohort. Included were EU-GEI participants who met CHR criteria at baseline and ALSPAC participants who did not report PEs at age 12 years. Data were analyzed from September 2018 to April 2020. Main Outcomes and Measures: In EU-GEI, transition status was assessed by the Comprehensive Assessment of At-Risk Mental States or contact with clinical services. In ALSPAC, PEs at age 18 years were assessed using the Psychosis-Like Symptoms Interview. Proteomic data were obtained from mass spectrometry of baseline plasma samples in EU-GEI and plasma samples at age 12 years in ALSPAC. Support vector machine learning algorithms were used to develop predictive models. Results: The EU-GEI subsample (133 participants at CHR (mean [SD] age, 22.6 [4.5] years; 68 [51.1%] male) comprised 49 (36.8%) who developed psychosis and 84 (63.2%) who did not. A model based on baseline clinical and proteomic data demonstrated excellent performance for prediction of transition outcome (area under the receiver operating characteristic curve [AUC], 0.95; positive predictive value [PPV], 75.0%; and negative predictive value [NPV], 98.6%). Functional analysis of differentially expressed proteins implicated the complement and coagulation cascade. A model based on the 10 most predictive proteins accurately predicted transition status in training (AUC, 0.99; PPV, 76.9%; and NPV, 100%) and test (AUC, 0.92; PPV, 81.8%; and NPV, 96.8%) data. The ALSPAC subsample (121 participants from the general population with plasma samples available at age 12 years (61 [50.4%] male) comprised 55 participants (45.5%) with PEs at age 18 years and 61 (50.4%) without PEs at age 18 years. A model using proteomic data at age 12 years predicted PEs at age 18 years, with an AUC of 0.74 (PPV, 67.8%; and NPV, 75.8%). Conclusions and Relevance: In individuals at risk of psychosis, proteomic biomarkers may contribute to individualized prognosis and stratification strategies. These findings implicate early dysregulation of the complement and coagulation cascade in the development of psychosis outcomes.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Altered structural brain asymmetry in autism spectrum disorder in a study of 54 datasets

  • Postema, Merel C.
  • van Rooij, Daan
  • Anagnostou, Evdokia
  • Arango, Celso
  • Auzias, Guillaume
  • Behrmann, Marlene
  • Filho, Geraldo Busatto
  • Calderoni, Sara
  • Calvo Escalona, Rosa
  • Daly, Eileen
  • Deruelle, Christine
  • Di Martino, Adriana
  • Dinstein, Illan
  • Duran, Fabio Luis S.
  • Durston, Sarah
  • Ecker, Christine
  • Ehrlich, Stefan
  • Fair, Damien
  • Fedor, Jennifer
  • Feng, Xin
  • FitzGerald, Jackie
  • Floris, Dorothea L.
  • Freitag, Christine M.
  • Gallagher, Louise
  • Glahn, David C.
  • Gori, Ilaria
  • Haar, Shlomi
  • Hoekstra, Liesbeth
  • Jahanshad, Neda
  • Jalbrzikowski, Maria
  • Janssen, Joost
  • King, Joseph A.
  • Kong, Xiang-Zhen
  • Lázaro García, Luisa
  • Lerch, Jason P.
  • Luna, Beatriz
  • Martinho, Mauricio M.
  • McGrath, Jane
  • Medland, Sarah E.
  • Muratori, Filippo
Altered structural brain asymmetry in autism spectrum disorder (ASD) has been reported. However, findings have been inconsistent, likely due to limited sample sizes. Here we investigated 1,774 individuals with ASD and 1,809 controls, from 54 independent data sets of the ENIGMA consortium. ASD was significantly associated with alterations of cortical thickness asymmetry in mostly medial frontal, orbitofrontal, cingulate and inferior temporal areas, and also with asymmetry of orbitofrontal surface area. These differences generally involved reduced asymmetry in individuals with ASD compared to controls. Furthermore, putamen volume asymmetry was significantly increased in ASD. The largest case-control effect size was Cohen's d = -0.13, for asymmetry of superior frontal cortical thickness. Most effects did not depend on age, sex, IQ, severity or medication use. Altered lateralized neurodevelopment may therefore be a feature of ASD, affecting widespread brain regions with diverse functions. Large-scale analysis was necessary to quantify subtle alterations of brain structural asymmetry in ASD.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

White noise speech illusions: a trait-dependent risk marker for psychotic disorder?

  • Schepers, Elaine
  • Lousberg, Richel
  • Guloksuz, Sinan
  • Pries, Lotta-Katrin
  • Delespaul, Philippe
  • Kenis, Gunter
  • Luykx, Jurjen J.
  • Lin, Bochao D.
  • Richards, Alexander L.
  • Akdede, Berna
  • Binbay, Tolga
  • Altınyazar, Vesile
  • Yalınçetin, Berna
  • Gümüş-Akay, Güvem
  • Cihan, Burçin
  • Soygür, Haldun
  • Ulas, Halis
  • Cankurtaran, Eylem Sahin
  • Bernardo Arroyo, Miquel
  • Cabrera Llorca, Bibiana
  • Kaymak, Semra Ulusoy
  • Mihaljevic, Marina M.
  • Petrovic, Sanja Andric
  • Mirjanic, Tijana
  • Bernardo Arroyo, Miquel
  • Bobes García, Julio
  • Sáiz Martínez, Pilar Alejandra
  • García-Portilla González, María Paz, 1962-
  • Sanjuan, Julio
  • Aguilar, Eduardo
  • Jiménez López, Estela
  • Arrojo, Manuel
  • Carracedo Álvarez, Ángel
  • López, Gonzalo
  • González Peñas, Javier
  • Parellada, Mara
  • Maric, Nadja P.
  • Atbaşoğlu, Cem
  • Ucok, Alp
  • Alptekin, Köksal
  • Can Saka, Meram
  • Arango, Celso
  • Rutten, Bart P.F.
  • van Os, Jim
Introduction: White noise speech illusions index liability for psychotic disorder in case-control comparisons. In the current study, we examined i) the rate of white noise speech illusions in siblings of patients with psychotic disorder and ii) to what degree this rate would be contingent on exposure to known environmental risk factors (childhood adversity and recent life events) and level of known endophenotypic dimensions of psychotic disorder [psychotic experiences assessed with the Community Assessment of Psychic Experiences (CAPE) scale and cognitive ability]. Methods: The white noise task was used as an experimental paradigm to elicit and measure speech illusions in 1,014 patients with psychotic disorders, 1,157 siblings, and 1,507 healthy participants. We examined associations between speech illusions and increasing familial risk (control -> sibling -> patient), modeled as both a linear and a categorical effect, and associations between speech illusions and level of childhood adversities and life events as well as with CAPE scores and cognitive ability scores. Results: While a positive association was found between white noise speech illusions across hypothesized increasing levels of familial risk (controls -> siblings -> patients) [odds ratio (OR) linear 1.11, 95% confidence interval (CI) 1.02-1.21, p = 0.019], there was no evidence for a categorical association with sibling status (OR 0.93, 95% CI 0.79-1.09, p = 0.360). The association between speech illusions and linear familial risk was greater if scores on the CAPE positive scale were higher (p interaction = 0.003; ORlow CAPE positive scale 0.96, 95% CI 0.85-1.07; ORhigh CAPE positive scale 1.26, 95% CI 1.09-1.46); cognitive ability was lower (p interaction < 0.001; ORhigh cognitive ability 0.94, 95% CI 0.84-1.05; ORlow cognitive ability 1.43, 95% CI 1.23-1.68); and exposure to childhood adversity was higher (p interaction < 0.001; ORlow adversity 0.92, 95% CI 0.82-1.04; ORhigh adversity 1.31, 95% CI 1.13-1.52). A similar, although less marked, pattern was seen for categorical patient-control and sibling-control comparisons. Exposure to recent life events did not modify the association between white noise and familial risk (p interaction = 0.232). Conclusion: The association between white noise speech illusions and familial risk is contingent on additional evidence of endophenotypic expression and of exposure to childhood adversity. Therefore, speech illusions may represent a trait-dependent risk marker.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Early Parental Death and Risk of Psychosis in Offspring: A Six-Country Case-Control Study

  • Misra, Supriya
  • Gelaye, Bizu
  • Koenen, Karestan C.
  • Williams, David R.
  • Borba, Christina P.C.
  • Quattrone, Diego
  • Di Forti, Marta
  • La Cascia, Caterina
  • La Barbera, Daniele
  • Tarricone, Ilaria
  • Berardi, Domenico
  • Szöke, Andrei
  • Arango, Celso
  • Tortelli, Andrea
  • de Haan, Lieuwe
  • Velthorst, Eva
  • Bobes García, Julio
  • Bernardo Arroyo, Miquel
  • Sanjuán, Julio
  • Santos, José Luis
  • Arrojo, Manuel
  • Del-Ben, Cristina Marta
  • Menezes, Paulo Rossi
  • Selten, Jean Paul
  • Jones, Peter B.
  • Kirkbride, James B.
  • EU-GEI WP2 Group
  • Rutten, Bart P.F.
  • van Os, Jim
  • Murray, Robin M.
  • Anderson, Charlotte Gayer
  • Morgan, Craig
Evidence for early parental death as a risk factor for psychosis in offspring is inconclusive. We analyzed data from a six-country, case-control study to examine the associations of early parental death, type of death (maternal, paternal, both), and child's age at death with psychosis, both overall and by ethnic group. In fully adjusted multivariable mixed-effects logistic regression models, experiencing early parental death was associated with 1.54-fold greater odds of psychosis (95% confidence interval (CI): 1.23, 1.92). Experiencing maternal death had 2.27-fold greater odds (95% CI: 1.18, 4.37), paternal death had 1.14-fold greater odds (95% CI: 0.79, 1.64), and both deaths had 4.42-fold greater odds (95% CI: 2.57, 7.60) of psychosis compared with no early parental death. Experiencing parental death between 11 and 16 years of age had 2.03-fold greater odds of psychosis than experiencing it before five years of age (95% CI: 1.02, 4.04). In stratified analyses, experiencing the death of both parents had 9.22-fold greater odds of psychosis among minority ethnic groups (95% CI: 2.02-28.02) and no elevated odds among the ethnic majority (odds ratio (OR): 0.96; 95% CI: 0.10-8.97), which could be due in part to the higher prevalence of early parental death among minority ethnic groups but should be interpreted cautiously given the wide confidence intervals.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinacional EU-GEI study

  • Quattrone, Diego
  • Di Forti, Marta
  • Gayer-Anderson, Charlotte
  • Ferraro, Laura
  • Jongsma, Hanna E.
  • Tripoli, Giada
  • La Cascia, Caterina
  • La Barbera, Daniele
  • Tarricone, Ilaria
  • Berardi, Domenico
  • Szöke, Andrei
  • Arango, Celso
  • Lasalvia, Antonio
  • Tortelli, Andrea
  • Llorca, Pierre Michel
  • de Haan, Lieuwe
  • Velthorst, Eva
  • Bobes García, Julio
  • Bernardo Arroyo, Miquel
  • Sanjuán, Julio
  • Arrojo, Manuel
  • Del-Ben, Cristina Marta
  • Menezes, Paulo Rossi
  • Selten, Jean Paul
  • EU-GEI WP2 Group
  • Jones, Peter B.
  • Kirkbride, James B.
  • Richards, Alexander L.
  • O'Donovan, Michael C.
  • Sham, Pak C.
  • Vassos, Evangelos
  • Rutten, Bart P.F.
  • van Os, Jim
  • Morgan, Craig
  • Lewis, Cathryn M.
  • Murray, Robin M.
  • Reininghaus, Ulrich
Background: The value of the nosological distinction between non-affective and affective psychosis has frequently been challenged. We aimed to investigate the transdiagnostic dimensional structure and associated characteristics of psychopathology at First Episode Psychosis (FEP). Regardless of diagnostic categories, we expected that positive symptoms occurred more frequently in ethnic minority groups and in more densely populated environments, and that negative symptoms were associated with indices of neurodevelopmental impairment. Method: This study included 2182 FEP individuals recruited across six countries, as part of the EUropean network of national schizophrenia networks studying Gene-Environment Interactions (EU-GEI) study. Symptom ratings were analysed using multidimensional item response modelling in Mplus to estimate five theory-based models of psychosis. We used multiple regression models to examine demographic and context factors associated with symptom dimensions. Results: A bifactor model, composed of one general factor and five specific dimensions of positive, negative, disorganization, manic and depressive symptoms, best-represented associations among ratings of psychotic symptoms. Positive symptoms were more common in ethnic minority groups. Urbanicity was associated with a higher score on the general factor. Men presented with more negative and less depressive symptoms than women. Early age-at-first-contact with psychiatric services was associated with higher scores on negative, disorganized, and manic symptom dimensions. Conclusions: Our results suggest that the bifactor model of psychopathology holds across diagnostic categories of non-affective and affective psychosis at FEP, and demographic and context determinants map onto general and specific symptom dimensions. These findings have implications for tailoring symptom-specific treatments and inform research into the mood-psychosis spectrum.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Opposite cannabis-cognition associations in psychotic patients depending on family history

  • González-Pinto, Ana
  • González Ortega, Itxaso
  • Alberich, Susana
  • Ruiz de Azúa, Sonia
  • Bernardo Arroyo, Miquel
  • Bioque Alcázar, Miquel
  • Cabrera, Bibiana
  • Corripio, Iluminada
  • Arango, Celso
  • Lobo, Antonio
  • Sánchez-Torres, Ana M.
  • Cuesta, Manuel J.
  • PEPs Group
The objective of this study is to investigate cognitive performance in a first-episode psycho- sis sample, when stratifying the interaction by cannabis use and familial or non-familial psy- chosis. Hierarchical-regression models were used to analyse this association in a sample of 268 first-episode psychosis patients and 237 controls. We found that cannabis use was associated with worse working memory, regardless of family history. However, cannabis use was clearly associated with worse cognitive performance in patients with no family his- tory of psychosis, in cognitive domains including verbal memory, executive function and global cognitive index, whereas cannabis users with a family history of psychosis performed better in these domains. The main finding of the study is that there is an interaction between cannabis use and a family history of psychosis in the areas of verbal memory, executive function and global cognition: that is, cannabis use is associated with a better performance in patients with a family history of psychosis and a worse performance in those with no fam- ily history of psychosis. In order to confirm this hypothesis, future research should explore the actual expression of the endocannabinoid system in patients with and without a family history of psychosis
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Polygenic contribution to the relationship of loneliness and social isolation with schizophrenia

  • Andreu-Bernabeu, Álvaro
  • Díaz-Caneja, Covadonga M.
  • Costas, Javier
  • De Hoyos, Lucía
  • Stella, Carol
  • Gurriarán, Xaquín
  • Alloza, Clara
  • Fañanás Saura, Lourdes
  • Bobes García, Julio
  • González-Pinto, Ana
  • Crespo-Facorro, Benedicto
  • Martorell, Lourdes
  • Vilella, Elisabet
  • Muntané, Gerard
  • Nacher, Juan
  • Moltó, M. Dolors
  • Aguilar, Eduardo Jesús
  • Parellada, Mara
  • Arango López, Celso
  • González-Peñas, Javier
Previous research suggests an association of loneliness and social isolation (LNL-ISO) with schizophrenia. Here, we demonstrate a LNL-ISO polygenic score contribution to schizophrenia risk in an independent case-control sample (N = 3,488). We then subset schizophrenia predisposing variation based on its effect on LNL-ISO. We find that genetic variation with concordant effects in both phenotypes shows significant SNP-based heritability enrichment, higher polygenic contribution in females, and positive covariance with mental disorders such as depression, anxiety, attention-deficit hyperactivity disorder, alcohol dependence, and autism. Conversely, genetic variation with discordant effects only contributes to schizophrenia risk in males and is negatively correlated with those disorders. Mendelian randomization analyses demonstrate a plausible bi-directional causal relationship between LNL-ISO and schizophrenia, with a greater effect of LNL-ISO liability on schizophrenia than vice versa. These results illustrate the genetic footprint of LNL-ISO on schizophrenia.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Association of Adverse Outcomes With Emotion Processing and Its Neural Substrate in Individuals at Clinical High Risk for Psychosis

  • Modinos, Gemma|||0000-0002-7870-066X
  • Kempton, Matthew|||0000-0003-3541-9947
  • Tognin, Stefania|||0000-0002-1983-9135
  • Calem, Maria
  • Porffy, Lilla
  • Antoniades, Mathilde
  • Mason, Ava
  • Azis, Matilda|||0000-0001-8164-0357
  • Allen, Paul
  • Nelson, Barnaby|||0000-0002-6263-2332
  • McGorry, Patrick|||0000-0002-3789-6168
  • Pantelis, Christos|||0000-0002-9565-0238
  • Riecher-Rössler, Anita|||0000-0001-6361-8789
  • Borgwardt, Stefan
  • Bressan, Rodrigo Affonseca|||0000-0002-0868-4449
  • Barrantes Vidal, Neus|||0000-0002-8671-1238
  • Krebs, Marie Odile|||0000-0002-4715-9890
  • Nordentoft, Merete|||0000-0003-4895-7023
  • Glenthøj, Birte|||0000-0003-3056-7262
  • Ruhrmann, Stephan|||0000-0002-6022-2364
  • Sachs, Gabriele|||0000-0002-8359-9877
  • Rutten, Bart P. F.|||0000-0002-9834-6346
  • Os, Jim Van|||0000-0002-7245-1586
  • Haan, Lieuwe de, 1960-|||0000-0002-3820-7926
  • Velthorst, Eva|||0000-0002-9240-2909
  • Gaag, Mark van der, 1953-|||0000-0002-3525-6415
  • Valmaggia, Lucia|||0000-0001-6099-8464
  • McGuire, Philip|||0000-0003-4381-0532
This case-control study analyzes emotion recognition and neuroimaging data as well as clinical and functional outcomes for individuals at risk for transition to psychosis and those without psychiatric or neurological disorders. Is altered emotion recognition associated with adverse clinical and functional outcomes in people at clinical high risk for psychosis? In this case-control study of 213 individuals at clinical high risk for psychosis and 52 healthy participants, abnormalities in the recognition of negative emotion at baseline were associated with neuroanatomical alterations in the medial prefrontal cortex and hippocampus and with a low level of functioning at a 12-month follow-up. This study found that, in people with high risk for developing psychosis, functional outcomes are associated with the degree to which their emotion processing is altered. The development of adverse clinical outcomes in patients with psychosis has been associated with behavioral and neuroanatomical deficits related to emotion processing. However, the association between alterations in brain regions subserving emotion processing and clinical outcomes remains unclear. To examine the association between alterations in emotion processing and regional gray matter volumes in individuals at clinical high risk (CHR) for psychosis, and the association with subsequent clinical outcomes. This naturalistic case-control study with clinical follow-up at 12 months was conducted from July 1, 2010, to August 31, 2016, and collected data from 9 psychosis early detection centers (Amsterdam, Basel, Cologne, Copenhagen, London, Melbourne, Paris, The Hague, and Vienna). Participants (213 individuals at CHR and 52 healthy controls) were enrolled in the European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) project. Data were analyzed from October 1, 2018, to April 24, 2019. Emotion recognition was assessed with the Degraded Facial Affect Recognition Task. Three-Tesla magnetic resonance imaging scans were acquired from all participants, and gray matter volume was measured in regions of interest (medial prefrontal cortex, amygdala, hippocampus, and insula). Clinical outcomes at 12 months were evaluated for transition to psychosis using the Comprehensive Assessment of At-Risk Mental States criteria, and the level of overall functioning was measured through the Global Assessment of Functioning [GAF] scale. A total of 213 individuals at CHR (105 women [49.3%]; mean [SD] age, 22.9 [4.7] years) and 52 healthy controls (25 women [48.1%]; mean [SD] age, 23.3 [4.0] years) were included in the study at baseline. At the follow-up within 2 years of baseline, 44 individuals at CHR (20.7%) had developed psychosis and 169 (79.3%) had not. Of the individuals at CHR reinterviewed with the GAF, 39 (30.0%) showed good overall functioning (GAF score, ≥65), whereas 91 (70.0%) had poor overall functioning (GAF score, <65). Within the CHR sample, better anger recognition at baseline was associated with worse functional outcome (odds ratio [OR], 0.88; 95% CI, 0.78-0.99; P = .03). In individuals at CHR with a good functional outcome, positive associations were found between anger recognition and hippocampal volume (z e = 3.91; familywise error [FWE] P = .02) and between fear recognition and medial prefrontal cortex volume (z = 3.60; FWE P = .02), compared with participants with a poor outcome. The onset of psychosis was not associated with baseline emotion recognition performance (neutral OR, 0.93; 95% CI, 0.79-1.09; P = .37; happy OR, 1.03; 95% CI, 0.84-1.25; P = .81; fear OR, 0.98; 95% CI, 0.85-1.13; P = .77; anger OR, 1.00; 95% CI, 0.89-1.12; P = .96). No difference was observed in the association between performance and regional gray matter volumes in individuals at CHR who developed or did not develop psychosis (FWE P < .05). In this study, poor functional outcome in individuals at CHR was found to be associated with baseline abnormalities in recognizing negative emotion. This finding has potential implications for the stratification of individuals at CHR and suggests that interventions that target socioemotional processing may improve functional outcomes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosis

  • Pollak, Thomas Arthur Nicholls|||0000-0002-6171-0810
  • Kempton, Matthew|||0000-0003-3541-9947
  • Iyegbe, Conrad
  • Vincent, Angela|||0000-0003-2395-8695
  • Irani, Sarosh R.
  • Coutinho, Ester
  • Menassa, David A.
  • Jacobson, Leslie
  • Haan, Lieuwe de, 1960-|||0000-0002-3820-7926
  • Ruhrmann, Stephan|||0000-0002-6022-2364
  • Sachs, Gabriele|||0000-0002-8359-9877
  • Riecher-Rössler, Anita|||0000-0001-6361-8789
  • Krebs, Marie Odile|||0000-0002-4715-9890
  • Amminger, G. Paul|||0000-0001-8969-4595
  • Glenthøj, Birte|||0000-0003-3056-7262
  • Barrantes Vidal, Neus|||0000-0002-8671-1238
  • Os, Jim Van|||0000-0002-7245-1586
  • Rutten, Bart P. F.|||0000-0002-9834-6346
  • Bressan, Rodrigo Affonseca|||0000-0002-0868-4449
  • Gaag, Mark van der, 1953-|||0000-0002-3525-6415
  • Yolken, Robert
  • Hotopf, Matthew|||0000-0002-3980-4466
  • Valmaggia, Lucia|||0000-0001-6099-8464
  • Stone, James|||0000-0003-3051-0135
  • David, Anthony S.
  • McGuire, Philip|||0000-0003-4381-0532
Serum neuronal autoantibodies, such as those to the NMDA receptor (NMDAR), are detectable in a subgroup of patients with psychotic disorders. It is not known if they are present before the onset of psychosis or whether they are associated with particular clinical features or outcomes. In a case-control study, sera from 254 subjects at clinical high risk (CHR) for psychosis and 116 healthy volunteers were tested for antibodies against multiple neuronal antigens implicated in CNS autoimmune disorders, using fixed and live cell-based assays (CBAs). Within the CHR group, the relationship between NMDAR antibodies and symptoms, cognitive function and clinical outcomes over 24 month follow-up was examined. CHR subjects were not more frequently seropositive for neuronal autoantibodies than controls (8.3% vs. 5.2%; OR = 1.50; 95% CI: 0.58-3.90). The NMDAR was the most common target antigen and NMDAR IgGs were more sensitively detected with live versus fixed CBAs (p < 0.001). Preliminary phenotypic analyses revealed that within the CHR sample, the NMDAR antibody seropositive subjects had higher levels of current depression, performed worse on the Rey Auditory Verbal Learning Task (p < 0.05), and had a markedly lower IQ (p < 0.01). NMDAR IgGs were not more frequent in subjects who later became psychotic than those who did not. NMDAR antibody serostatus and titre was associated with poorer levels of functioning at follow-up (p < 0.05) and the presence of a neuronal autoantibody was associated with larger amygdala volumes (p < 0.05). Altogether, these findings demonstrate that NMDAR autoantibodies are detectable in a subgroup of CHR subjects at equal rates to controls. In the CHR group, they are associated with affective psychopathology, impairments in verbal memory, and overall cognitive function: these findings are qualitatively and individually similar to core features of autoimmune encephalitis and/or animal models of NMDAR antibody-mediated CNS disease. Overall the current work supports further evaluation of NMDAR autoantibodies as a possible prognostic biomarker and aetiological factor in a subset of people already meeting CHR criteria.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Obsessive-Compulsive Symptoms and Other Symptoms of the At-risk Mental State for Psychosis, A Network Perspective

  • Ong, Hui Lin
  • Isvoranu, Adela-Maria|||0000-0001-7981-9198
  • Schirmbeck, Frederike|||0000-0003-1700-0958
  • McGuire, Philip|||0000-0003-4381-0532
  • Valmaggia, Lucia|||0000-0001-6099-8464
  • Kempton, Matthew|||0000-0003-3541-9947
  • Gaag, Mark van der, 1953-|||0000-0002-3525-6415
  • Riecher-Rössler, Anita|||0000-0001-6361-8789
  • Bressan, Rodrigo Affonseca|||0000-0002-0868-4449
  • Barrantes Vidal, Neus|||0000-0002-8671-1238
  • Nelson, Barnaby|||0000-0002-6263-2332
  • Amminger, G. Paul|||0000-0001-8969-4595
  • McGorry, Patrick|||0000-0002-3789-6168
  • Pantelis, Christos|||0000-0002-9565-0238
  • Krebs, Marie Odile|||0000-0002-4715-9890
  • Nordentoft, Merete|||0000-0003-4895-7023
  • Glenthøj, Birte|||0000-0003-3056-7262
  • Ruhrmann, Stephan|||0000-0002-6022-2364
  • Sachs, Gabriele|||0000-0002-8359-9877
  • Rutten, Bart P. F.|||0000-0002-9834-6346
  • Os, Jim Van|||0000-0002-7245-1586
  • Haan, Lieuwe de, 1960-|||0000-0002-3820-7926
  • Borsboom, Denny|||0000-0001-9720-4162
The high prevalence of obsessive-compulsive symptoms (OCS) among subjects at Ultra-High Risk (UHR) for psychosis is well documented. However, the network structure spanning the relations between OCS and symptoms of the at risk mental state for psychosis as assessed with the Comprehensive Assessment of At Risk Mental States (CAARMS) has not yet been investigated. This article aimed to use a network approach to investigate the associations between OCS and CAARMS symptoms in a large sample of individuals with different levels of risk for psychosis. Three hundred and forty-one UHR and 66 healthy participants were included, who participated in the EU-GEI study. Data analysis consisted of constructing a network of CAARMS symptoms, investigating central items in the network, and identifying the shortest pathways between OCS and positive symptoms. Strong associations between OCS and anxiety, social isolation and blunted affect were identified. Depression was the most central symptom in terms of the number of connections, and anxiety was a key item in bridging OCS to other symptoms. Shortest paths between OCS and positive symptoms revealed that unusual thought content and perceptual abnormalities were connected mainly via anxiety, while disorganized speech was connected via blunted affect and cognitive change. Findings provide valuable insight into the central role of depression and the potential connective component of anxiety between OCS and other symptoms of the network. Interventions specifically aimed to reduce affective symptoms might be crucial for the development and prospective course of symptom co-occurrence.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Opposite Cannabis-Cognition Associations in Psychotic Patients Depending on Family History

  • González-Pinto, Ana|||0000-0002-2568-5179
  • González-Ortega, Itxaso|||0000-0001-7074-4353
  • Alberich, Susana|||0000-0002-4945-3428
  • Ruiz de Azúa, Sonia
  • Bernardo, Miquel|||0000-0001-8748-6717
  • Bioque, Miquel|||0000-0001-6887-7149
  • Cabrera, Bibiana|||0000-0002-7749-5449
  • Corripio, Iluminada|||0000-0003-2562-711X
  • Arango, Celso|||0000-0003-3382-4754
  • Lobo, Antonio|||0000-0002-9098-655X
  • Sánchez Torres, Ana Maria|||0000-0002-9505-2406
  • Cuesta, Manuel J.|||0000-0003-0250-5718
The objective of this study is to investigate cognitive performance in a first-episode psychosis sample, when stratifying the interaction by cannabis use and familial or non-familial psychosis. Hierarchical-regression models were used to analyse this association in a sample of 268 first-episode psychosis patients and 237 controls. We found that cannabis use was associated with worse working memory, regardless of family history. However, cannabis use was clearly associated with worse cognitive performance in patients with no family history of psychosis, in cognitive domains including verbal memory, executive function and global cognitive index, whereas cannabis users with a family history of psychosis performed better in these domains. The main finding of the study is that there is an interaction between cannabis use and a family history of psychosis in the areas of verbal memory, executive function and global cognition: that is, cannabis use is associated with a better performance in patients with a family history of psychosis and a worse performance in those with no family history of psychosis. In order to confirm this hypothesis, future research should explore the actual expression of the endocannabinoid system in patients with and without a family history of psychosis.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Genetic and psychosocial stressors have independent effects on the level of subclinical psychosis: findings from the multinational EU-GEI study

  • Pignon, B.
  • Peyre, H.
  • Ayrolles, A.
  • Bobes, Julio|||0000-0003-2187-4033
the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by ERDF Funds from the European Commission, ‘A way of making Europe’, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI) and FP7-HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS) (...), Pignon B, Peyre H, Ayrolles A, Kirkbride JB, Jamain S, Ferchiou A, Richard JR, Baudin G, Tosato S, Jongsma H, de Haan L, Tarricone I, Bernardo M, Velthorst E, Braca M, Arango C, Arrojo M, Bobes J, Del-Ben CM, Di Forti M, Gayer-Anderson C, Jones PB, La Cascia C, Lasalvia A, Menezes PR, Quattrone D, Sanjuán J, Selten JP, Tortelli A, Llorca PM, van Os J, Rutten BPF, Murray RM, Morgan C, Leboyer M, Szöke A, Schürhoff F
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Exploring the mediation of dna methylation across the epigenome between childhood adversity and first episode of psychosis—findings from the EU-GEI study

  • Alameda, L.
  • Liu, Z.
  • Sham, P. C.
  • Bobes, Julio|||0000-0003-2187-4033
The EU-GEI Project is funded by the European Community’s Seventh Framework Programme under grant agreement No. HEALTH-F2-2010-241909 (Project EU-GEI); Craig Morgan is part funded by the ESRC (ESRC Centre for Society and Mental Health at King’s College London: ESRC Reference: ES/S012567/1), and the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London., Alameda L., Liu Z., Sham P.C., Aas M., Trotta G., Rodriguez V., Di Forti M., Stilo S.A., Kandaswamy R., Arango C., Arrojo M., Bernardo M., Bobes J., de Haan L., Del-Ben C.M., Gayer-Anderson C., Sideli L., Jones P.B., Jongsma H.E., Kirkbride J.B., La Cascia C., Lasalvia A., Tosato S., Llorca P.-M., Menezes P.R., van Os J., Quattrone D., Rutten B.P., Santos J.L., Sanjuán J., Selten J.-P., Szöke A., Tarricone I., Tortelli A., Velthorst E., Morgan C., Dempster E., Hannon E., Burrage J., Dwir D., Arumuham A., Mill J., Murray R.M., Wong C.C.Y.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Examining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: results from the EUGEI study

  • Fusar Poli, L.
  • Prachason, T.
  • Erzin, G.
  • Bobes, Julio|||0000-0003-2187-4033
  • Saiz Martínez, Pilar Alejandra
  • García-Portilla González, María Paz|||0000-0003-3643-1622
  • Outcome of Psychosis (GROUP)
The EUGEI project was supported by the grant agreement HEALTHF2-2010-241909 from the European Community’s Seventh Framework Programme. Dr Arango was supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), co-financed by the European Union, ERDF Funds from the European Commission, “A way of making Europe”, financed by the European Union - NextGenerationEU (PMP21/00051), PI19/01024. CIBERSAM, Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds, European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (Grant agreement No.101034377), Project AIMS-2-TRIALS (Grant agreement No 777394), Horizon Europe, the National Institute of Mental Health of the National Institutes of Health under Award Number 1U01MH124639-01 (Project ProNET) and Award Number 5P50MH115846-03 (project FEP-CAUSAL), Fundación Familia Alonso, and Fundación Alicia Koplowitz. Drs. Bobes, García-Portilla, and Sáiz have received partial support from the Government of the Principality of Asturias PCTI-2021-2023 IDI/2021/111, the Fundación para la Investigación e Innovación Biosanitaria del Principado de Asturias (FINBA), and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, and Ministerio de Ciencia e Innovacion (...), Fusar-Poli, L., Prachason, T., Erzin, G., Pries, L.-K., Brondino, N., Politi, P., Delespaul, P., Kenis, G., Luykx, J.J., Lin, B.D., Richards, A.L., Akdede, B., Binbay, T., Altınyazar, V., Yalınçetin, B., Gümüş-Akay, G., Cihan, B., Soygür, H., Ulaş, H., Cankurtaran, E.Ş., Kaymak, S.U., Mihaljevic, M.M., Andric-Petrovic, S., Mirjanic, T., Bernardo, M., Mezquida, G., Amoretti, S., Bobes, J., Saiz, P.A., García-Portilla, M.P., Sanjuan, J., Escarti, M.J., Santos, J.L., Jiménez-López, E., Arrojo, M., Carracedo, A., López, G., González-Peñas, J., Parellada, M., Maric, N.P., Atbaşoğlu, C., Üçok, A., Alptekin, K., Saka, M.C., Arango, C., O'Donovan, M., van Os, J., Rutten, B.P., Guloksuz, S., Genetic Risk and Outcome of Psychosis (GROUP) investigators
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

The effect of polygenic risk score and childhood adversity on transdiagnostic symptom dimensions at first-episode psychosis: evidence for an affective pathway to psychosis

  • Alameda, L.
  • Rodríguez, V.
  • Di Forti, M.
  • Bobes, Julio|||0000-0003-2187-4033
We thank all the contributors to the EU-GEI (WP2 group) study for their hard work. The EU-GEI Project is funded by the European Community’s Seventh Framework Programme under grant agreement No. HEALTH-F2- 2010-241909 (Project EU-GEI). Dr Luis Alameda thanks the Foundation Adrian and Simone Frutiger Foundation and Carigest SA Foundation for their support. Dr Aas is funded by the MRC (#MR/ W027720/1)., Alameda L., Rodriguez V., Di Forti M., Spinazzola E., Trotta G., Arango C., Arrojo M., Bernardo M., Bobes J., de Haan L., Del-Ben C.M., Gayer-Anderson C., Sideli L., Jones P.B., Kirkbride J.B., La Cascia C., Tripoli G., Ferraro L., La Barbera D., Lasalvia A., Tosato S., Llorca P.-M., Menezes P.R., van Os J., Rutten B.P., Santos J.L., Sanjuán J., Selten J.-P., Szöke A., Tarricone I., Tortelli A., Velthorst E., Jongsma H.E., Vassos E., Quattrone D., Murray R.M., Aas M.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

White noise speech illusions: A trait-dependent risk marker for psychotic disorder?

  • Schepers, Elaine
  • Lousberg, Richel
  • Guloksuz, Sinan
  • Bobes, Julio|||0000-0003-2187-4033
  • Saiz Martínez, Pilar Alejandra
  • García-Portilla González, María Paz|||0000-0003-3643-1622
Supported by the European Community’s Seventh Framework Program under grant agreement No. HEALTH-F2-2009-241909 (Project EU-GEI), Schepers, E., Lousberg, R., Guloksuz, S., Pries, L.-K., Delespaul, P., Kenis, G., Luykx, J.J., Lin, B.D., Richards, A.L., Akdede, B., Binbay, T., Altınyazar, V., Yalınçetin, B., Gümüş-Akay, G., Cihan, B., Soygür, H., Ulaş, H., Cankurtaran, E.Ş., Kaymak, S.U., Mihaljevic, M.M., Petrovic, S.A., Mirjanic, T., Bernardo, M., Cabrera, B., Bobes, J., Saiz, P.A., García-Portilla, M.P., Sanjuan, J., Aguilar, E.J., Santos, J.L., Jiménez-López, E., Arrojo, M., Carracedo, A., López, G., González-Peñas, J., Parellada, M., Maric, N.P., Atbaşoğlu, C., Ucok, A., Alptekin, K., Saka, M.C., Arango, C., Rutten, B.P.F., van Os, J.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Childhood adversities and psychosis across populations: insights from the 6-country EU-GEI study

  • Morgan, Craig
  • Gayer Anderson, Charlotte
  • Sideli, Lucía
  • Bobes, Julio|||0000-0003-2187-4033
EU-GEI was funded by the European Community’s Seventh Framework Programme (grant number: HEALTH-F2-2010- 241909, Project EU-GEI), by the São Paulo Research Foundation (grant number: 2012/0417-0), and by the UK Economic and Social Research Council (grant numbers: ES/S012567/1 & UKRI861), Morgan C., Gayer-Anderson C., Sideli L., Jongsma H.E., Velthorst E., Tarricone I., Ferraro L., La Barbera D., La Cascia C., Lasalvia A., Tosato S., Berardi D., Arango C., Arrojo M., Bernardo M., Bobes J., Sanjuán J., Santos J.L., Rossi P.M., Del-Ben C.M., Llorca P.-M., Tortelli A., Szoke A., de Haan L., Selten J.-P., Van Os J., Rutten B.P., Di Forti M., Jones P.B., Kirkbride J.B., Murray R.M.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Examining the association between exposome score for schizophrenia and functioning in schizophrenia, siblings, and healthy controls: results from the EUGEI study

  • Erzin, G.
  • Pries, L. K.
  • Bobes, Julio|||0000-0003-2187-4033
  • Saiz Martínez, Pilar Alejandra
  • García-Portilla González, María Paz|||0000-0003-3643-1622
European Community's Seventh Framework Program, European Commission [HEALTH-F2-2009-241909]; Scientific and Technological Research Council of Turkey, 2219 International Postdoctoral Research Fellowship Program; Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, and PI19/024)..., Erzin, G., Pries, L.-K., van Os, J., Fusar-Poli, L., Delespaul, P., Kenis, G., Luykx, J.J., Lin, B.D., Richards, A.L., Akdede, B., Binbay, T., Altınyazar, V., Yalınçetin, B., Gümüş-Akay, G., Cihan, B., Soygür, H., Ulaş, H., Cankurtaran, E.Ş., Kaymak, S.U., Mihaljevic, M.M., Andric-Petrovic, S., Mirjanic, T., Bernardo, M., Mezquida, G., Amoretti, S., Bobes, J., Saiz, P.A., García-Portilla, M.P., Sanjuan, J., Aguilar, E.J., Santos, J.L., Jiménez-López, E., Arrojo, M., Carracedo, A., López, G., González-Peñas, J., Parellada, M., Maric, N.P., Atbaşoğlu, C., Ucok, A., Alptekin, K., Saka, M.C., Arango, C., O'Donovan, M.C., Rutten, B.P.F., Guloksuz, S., Genetic Risk and Outcome of Psychosis (GROUP) investigators
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

The association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: results from the EUGEI study

  • Fusar Poli, L.
  • Pries, L.-K.
  • Van Os, J.
  • Bobes, Julio|||0000-0003-2187-4033
  • Saiz Martínez, Pilar Alejandra
  • García-Portilla González, María Paz|||0000-0003-3643-1622
  • Genetic Risk and Outcome of Psychosis (GROUP) investigators
European Community, FP7 [HEALTH-F2-2009-241909]; Spanish Ministry of Science and Innovation; Instituto de Salud Carlos III [SAM16PE07CP1, PI16/02012, PI19/024]; CIBERSAM; Madrid Regional Government [B2017/BMD-3740 AGES-CM-2]; Fundación Familia Alonso and Fundación Alicia Koplowitz, Fusar-Poli, L., Pries, L.-K., van Os, J., Radhakrishnan, R., Pençe, A.Y., Erzin, G., Delespaul, P., Kenis, G., Luykx, J.J., Lin, B.D., Akdede, B., Binbay, T., Altınyazar, V., Yalınçetin, B., Gümüş-Akay, G., Cihan, B., Soygür, H., Ulaş, H., Cankurtaran, E.Ş., Kaymak, S.U., Mihaljevic, M.M., Andric-Petrovic, S., Mirjanic, T., Bernardo, M., Mezquida, G., Amoretti, S., Bobes, J., Saiz, P.A., García-Portilla, M.P., Sanjuan, J., Aguilar, E.J., Santos, J.L., Jiménez-López, E., Arrojo, M., Carracedo, A., López, G., González-Peñas, J., Parellada, M., Maric, N.P., Atbaşoğlu, C., Üçok, A., Alptekin, K., Saka, M.C., Aguglia, E., Arango, C., Rutten, B.P., Guloksuz, S., Genetic Risk and Outcome of Psychosis (GROUP) investigators
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

A replication study of JTC bias, genetic liability for psychosis and delusional ideation

  • Henquet C.
  • Van Os J.
  • Pries L.K.
  • Bobes, Julio|||0000-0003-2187-4033
  • Saiz Martínez, Pilar Alejandra
  • García-Portilla González, María Paz|||0000-0003-3643-1622
The EUGEI project was supported by the European Community's Seventh Framework Program under grant agreement No. HEALTH-F2-2009-241909 (Project EU-GEI). Dr O'Donovan is supported by MRC programme grant (G08005009) and an MRC Centre grant (MR/L010305/1), Henquet, C., Van Os, J., Pries, L.K., Rauschenberg, C., Delespaul, P., Kenis, G., Luykx, J.J., Lin, B.D., Richards, A.L., Akdede, B., Binbay, T., Altlnyazar, V., Yallnçetin, B., Gümüş-Akay, G., Cihan, B., Soygür, H., Ulaş, H., Cankurtaran, E.S., Kaymak, S.U., Mihaljevic, M.M., Petrovic, S.S., Mirjanic, T., Bernardo, M., Mezquida, G., Amoretti, S., Bobes, J., Saiz, P.A., Garciá-Portilla, M.P., Sanjuan, J., Aguilar, E.J., Santos, J.L., Jiménez-López, E., Arrojo, M., Carracedo, A., López, G., González-Penãs, J., Parellada, M., Maric, N.P., Atbaşoelu, C., Ucok, A., Alptekin, K., Saka, M.C., Arango, C., O'Donovan, M., Rutten, B.P.F., Gülöksüz, S.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Recent natural selection conferred protection against schizophrenia by non-antagonistic pleiotropy

  • González Peñas, J.
  • Hoyos, Lucía de
  • Díaz Caneja, C. M.
  • Bobes, Julio|||0000-0003-2187-4033
This work was supported by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI17/00997, PI19/01024, PI20/00721), co-financed by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7- HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz and Fundación Mutua Madrileña. J González-Peñas holds a Sara Borrel from Instituto de Salud Carlos III (CD20/00118). C. M. Díaz-Caneja holds a Juan Rodés Grant from Instituto de Salud Carlos III (JR19/00024)
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Variation of subclinical psychosis across 16 sites in Europe and brazil: findings from the multi-national eu-gei study

  • D'Andrea, Giuseppe
  • Quattrone, Diego
  • Malone, Kathryn
  • Bobes, Julio|||0000-0003-2187-4033
Project EU-GEI from the Seventh Framework Programme [HEALTH-F2-2010-241909]; Sao Paulo Research Foundation [2012/0417-0], D'Andrea G., Quattrone D., Malone K., Tripoli G., Trotta G., Spinazzola E., Gayer-Anderson C., Jongsma H.E., Sideli L., Stilo S.A., La Cascia C., Ferraro L., Lasalvia A., Tosato S., Tortelli A., Velthorst E., De Haan L., Llorca P.-M., Rossi Menezes P., Santos J.L., Arrojo M., Bobes J., Sanjuán J., Bernardo M., Arango C., Kirkbride J.B., Jones P.B., Rutten B.P., Van Os J., Selten J.-P., Vassos E., Schürhoff F., Szöke A., Pignon B., O'donovan M., Richards A., Morgan C., Di Forti M., Tarricone I., Murray R.M.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Self-reported suicidal ideation among individuals with first episode psychosis and healthy controls: findings from the international multicentre eu-gei study

  • Heuschen, C. B. B. C. M.
  • Bolhuis, K.
  • Zantvoord, J. B.
  • Bobes, Julio|||0000-0003-2187-4033
European Community's Seventh Framework Programme [HEALTH-F2- 2010-241909]; Sao Paulo Research Foundation [2012/0417-0], Heuschen C.B.B.C.M., Bolhuis K., Zantvoord J.B., Bockting C.L., Denys D.A.J.P., Lok A., Arango C., Arrojo M., Bernardo M., Bobes J., Del-Ben C.M., Di Forti M., Gayer-Anderson C., Jones P.B., Jongsma H.E., Kirkbride J.B., La Cascia C., Lasalvia A., Tosato S., Llorca P.M., Menezes P.R., Murray R.M., Quattrone D., Rutten B.P., Sanjuán J., Selten J.P., Szöke A., Tarricone I., Tortelli A., Velthorst E., de Haan L., Schirmbeck F.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Examining facial emotion recognition as an intermediate phenotype for psychosis: findings from the EUGEI study

  • Fusar Poli, L.
  • Pries, L. K.
  • Van Os, J.
  • Bobes, Julio|||0000-0003-2187-4033
  • Saiz Martínez, Pilar Alejandra
  • García-Portilla González, María Paz|||0000-0003-3643-1622
The EUGEI project was supported by the European Community’s Seventh Framework Program under grant agreement No. HEALTH-F2- 2009-241909 (Project EU-GEI). Dr. Arango was supported by the Spanish Ministry of Science and Innovation; Instituto de Salud Carlos III (SAM16-PE07CP1, PI16/02012, PI19/024); CIBERSAM (...), Fusar-Poli, L; Pries, LK; van Os, J; Erzin, G; Delespaul, P; Kenis, G; Luykx, JJ; Lin, BCD; Richards, AL; Akdede, B; Binbay, T; Altinyazar, V; Yalincetin, B; Gumus-Akay, G; Cihan, B; Soygur, H; Ulas, H; Cankurtaran, ES; Kaymak, SU; Mihaljevic, MM; Andric-Petrovic, S; Mirjanic, T; Bernardo, M; Mezquida, G; Amoretti, S; Bobes, J; Saiz, PA; Garcia-Portilla, MP; Sanjuan, J; Aguilar, EJ; Santos, JL; Jimenez-Lopez, E; Arrojo, M; Carracedo, A; Lopez, G; Gonzalez-Penas, J; Parellada, M; Maric, NP; Atbasoglu, C; Ucok, A; Alptekin, K; Saka, MC; Aguglia, E; Arango, C; O'Donovan, M; Rutten, BPF; Guloksuz, S
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Polygenic contribution to the relationship of loneliness and social isolation with schizophrenia

  • Andreu Bernabeu, Á.
  • Díaz Caneja, C. M.
  • Costas, J.
  • De Hoyos, L.
  • Stella, C.
  • Gurriarán, X.
  • Alloza, C.
  • Fañanás, L.
  • Bobes, Julio|||0000-0003-2187-4033
This work was supported by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI17/00997, PI19/01024, PI20/00721), co-financed by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN), and FP7- HEALTH-2013-2.2.1-2- 602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz, and Fundación Mutua Madrileña. We are grateful to Paloma Pantoja for her assistance in the design of the figures. A.A.-B. holds a Rio Hortega Grant from Instituto de Salud Carlos III (CM20/00114). C.M.D.-C. holds a Juan Rodés Grant from Instituto de Salud Carlos III (JR19/00024)., Andreu-Bernabeu, Á., Díaz-Caneja, C.M., Costas, J., De Hoyos, L., Stella, C., Gurriarán, X., Alloza, C., Fañanás, L., Bobes, J., González-Pinto, A., Crespo-Facorro, B., Martorell, L., Vilella, E., Muntané, G., Nacher, J., Molto, M.D., Aguilar, E.J., Parellada, M., Arango, C., González-Peñas, J.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Synergistic effects of childhood adversity and polygenic risk in first-episode psychosis: the EU-GEI study

  • Aas, M.
  • Alameda, L.
  • Di Forti, M.
  • Bobes, Julio|||0000-0003-2187-4033
The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) Project is funded by grant agreement HEALTH-F2-2010-241909 (Project EU-GEI) from the European Community’s Seventh Framework Programme., Aas, M; Alameda, L; Di Forti, M; Quattrone, D; Dazzan, P; Trotta, A; Ferraro, L; Rodriguez, V; Vassos, E; Sham, P; Tripoli, G; La Cascia, C; La Barbera, D; Tarricone, I; Muratori, R; Berardi, D; Lasalvia, A; Tosato, S; Szoke, A; Llorca, PM; Arango, C; Tortelli, A; de Haan, L; Velthorst, E; Bobes, J; Bernardo, M; Sanjuan, J; Santos, JL; Arrojo, M; Del-Ben, CM; Menezes, PR; Selten, JP; Jones, PB; Jongsma, HE; Kirkbride, JB; Rutten, BPF; van Os, J; Gayer-Anderson, C; Murray, RM; Morgan, C
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum

  • Pries, L. K.
  • Dal Ferro, G. A.
  • Bobes, Julio|||0000-0003-2187-4033
  • Saiz Martínez, Pilar Alejandra
  • García-Portilla González, María Paz|||0000-0003-3643-1622
The EUGEI project was supported by the European Community’s Seventh Framework Program under grant agreement no. HEALTH-F2-2009-241909 (Project EU-GEI). Dr O’Donovan is supported by MRC programme grant (G08005009) and an MRC Centre grant (MR/ L010305/1). Dr Rutten was funded by a VIDI award number 91718336 from the Netherlands Scientific Organisation. Drs Guloksuz and van Os are supported by the Ophelia research project, ZonMw grant number: 636340001. Dr Arango was supported by the Spanish Ministry of Science and Innovation; Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024); CIBERSAM; Madrid Regional Government (B2017/BMD-3740, AGES-CM-2); Fundación Familia Alonso and Fundación Alicia Koplowitz., Pries, L.-K., Dal Ferro, G.A., Van Os, J., Delespaul, P., Kenis, G., Lin, B.D., Luykx, J.J., Richards, A.L., Akdede, B., Binbay, T., Altlnyazar, V., Yallnçetin, B., Gümüş-Akay, G., Cihan, B., Soygür, H., Ulaş, H., Åžahin Cankurtaran, E., Ulusoy Kaymak, S., Mihaljevic, M.M., Andric Petrovic, S., Mirjanic, T., Bernardo, M., Mezquida, G., Amoretti, S., Bobes, J., Saiz, P.A., Garciá-Portilla, M.P., Sanjuan, J., Aguilar, E.J., Santos, J.L., Jiménez-López, E., Arrojo, M., Carracedo, A., López, G., González-Penãs, J., Parellada, M., Maric, N.P., AtbaşoÄalu, C., Ucok, A., Alptekin, K., Can Saka, M., Arango, C., O'Donovan, M., Tosato, S., Rutten, B.P.F., Guloksuz, S., and Genetic Risk and Outcome of Psychosis (GROUP) investigators
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Polygenic and polyenvironment interplay in schizophrenia-spectrum disorder and affective psychosis, the eugei first episode study

  • Rodríguez, Victoria
  • Alameda, Luis
  • Aas, Mónica
  • Bobes, Julio|||0000-0003-2187-4033
This work was supported by funding from the European Community’s Seventh Framework Programme under grant agreement No. HEALTH-F2-2010-241909 (Project EU-GEI). CA was supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), co-financed by the European Union, ERDF Funds from the European Commission, “A way of making Europe,” financed by the European Union-NextGenerationEU (PMP21/00051), PI19/01024. European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (Grant agreement No.101034377), Project AIMS-2-TRIALS (Grant agreement No 777394), Horizon Europe (...) MB was supported by the Ministry od Economy and Competitivity (PI08/0208; PI11/00325; PI14/00612), Instituto de Salud Carlos III–ERDF Funds from the European Commission, “A way of making Europe,” (...), Rodriguez V., Alameda L., Aas M., Gayer-Anderson C., Trotta G., Spinazzola E., Quattrone D., Tripoli G., Jongsma H.E., Stilo S., Cascia C.L., Ferraro L., Barbera D.L., Lasalvia A., Tosato S., Tarricone I., Bonora E., Jamain S., Selten J.-P., Velthorst E., de Haan L., Llorca P.-M., Arrojo M., Bobes J., Bernardo M., Arango C., Kirkbride J., Jones P.B., Rutten B.P., Richards A., Sham P.C., O’Donovan M., Van Os J., Morgan C., Forti M.D., Murray R.M., Vassos E.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Duration of untreated psychosis in first-episode psychosis is not associated with common genetic variants for major psychiatric conditions: results from the multi-center EU-GEI study

  • Ajnakina, O.
  • Rodríguez, V.
  • Quattrone, D.
  • Bobes, Julio|||0000-0003-2187-4033
  • EU-GEI WP2
The EU-GEI Project is funded by the European Community’s Seventh Framework Programme under grant agreement No. HEALTH-F2-2010–241909 (Project EU-GEI)., Ajnakina, O., Rodriguez, V., Quattrone, D., Di Forti, M., Vassos, E., Arango, C., Berardi, D., Bernardo, M., Bobes, J., De Haan, L., Del-Ben, C.M., Gayer-Anderson, C., Jongsma, H.E., Lasalvia, A., Tosato, S., Llorca, P.-M., Menezes, P.R., Rutten, B.P., Santos, J.L., Sanjuán, J., Selten, J.-P., Szöke, A., Tarricone, I., D'andrea, G., Richards, A., Tortelli, A., Velthorst, E., Jones, P.B., Arrojo Romero, M., La Cascia, C., Kirkbride, J.B., Van Os, J., O'donovan, M., Murray, R.M., EU-GEI WP2 Group
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the eu-gei case-control and uk biobank studies

  • Austin Zimmerman, I.
  • Spinazzola, E.
  • Quattrone, D.
  • Bobes, Julio|||0000-0003-2187-4033
The EU-GEI project was funded by the European Community’s Seventh Framework Programme under grant agreement No. HEALTH-F2-2009-241909 (Project EU-GEI). Dr Arango receives support from the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), co-financed by the European Union, ERDF Funds from the European Commission, ‘A way of making Europe’, financed by the European Union – NextGenerationEU (PMP21/00051), PI19/01024. CIBERSAM, Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds, European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (grant agreement No. 101034377), Project AIMS-2-TRIALS (grant agreement No. 777394), Horizon Europe, the National Institute of Mental Health of the National Institutes of Health under Award Number 1U01MH124639-01 (Project ProNET) and Award Number 5P50MH115846-03 (project FEP-CAUSAL), Fundación Familia Alonso, and Fundación Alicia Koplowitz (...), Austin-Zimmerman I., Spinazzola E., Quattrone D., Wu-Choi B., Trotta G., Li Z., Johnson E., Richards A.L., Freeman T.P., Tripoli G., Gayer-Anderson C., Rodriguez V., Jongsma H.E., Ferraro L., La Cascia C., Tosato S., Tarricone I., Berardi D., Bonora E., Seri M., D'Andrea G., Szöke A., Arango C., Bobes J., Sanjuán J., Santos J.L., Arrojo M., Velthorst E., Bernardo M., Del-Ben C.M., Rossi Menezes P., Selten J.-P., Jones P.B., Kirkbride J.B., Rutten B.P.F., Tortelli A., Llorca P.-M., De Haan L., Stilo S., La Barbera D., Lasalvia A., Schurnhoff F., Pignon B., Van Os J., Lynskey M., Morgan C., O' Donovan M., Lewis C.M., Sham P.C., Murray R.M., Vassos E., Di Forti M.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: The EU-GEI case-control study

  • Quattrone, D.
  • Ferraro, L.
  • Tripoli, G.
  • La Cascia, C.
  • Quigley, H.
  • Quattrone, A.
  • Jongsma, H. E.
  • Del Peschio, S.
  • Gatto, G.
  • Gayer Anderson, C.
  • Jones, P. B.
  • Kirkbride, J. B.
  • La Barbera, D.
  • Tarricone, I.
  • Berardi, D.
  • Tosato, S.
  • Lasalvia, A.
  • Szöke, A.
  • Arango, C.
  • Bernardo, M.
  • Bobes, Julio|||0000-0003-2187-4033
The work was supported by: Clinician Scientist Medical Research Council fellowship (project reference MR/M008436/1) to MDF; the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South London at King’s College Hospital NHS Foundation Trust to DQ; DFG Heisenberg professorship (no. 389624707) to UR. National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The EU-GEI Project is funded by the European Community’s Seventh Framework Programme under grant agreement No. HEALTH-F2-2010-241909 (Project EU-GEI). The Brazilian study was funded by the São Paulo Research Foundation under grant number 2012/0417-0., Quattrone, D., Ferraro, L., Tripoli, G., La Cascia, C., Quigley, H., Quattrone, A., Jongsma, H.E., Del Peschio, S., Gatto, G., Gayer-Anderson, C., Jones, P.B., Kirkbride, J.B., La Barbera, D., Tarricone, I., Berardi, D., Tosato, S., Lasalvia, A., Szöke, A., Arango, C., Bernardo, M., Bobes, J., Del Ben, C.M., Menezes, P.R., Llorca, P.-M., Santos, J.L., Sanjuán, J., Tortelli, A., Velthorst, E., De Haan, L., Rutten, B.P.F., Lynskey, M.T., Freeman, T.P., Sham, P.C., Cardno, A.G., Vassos, E., Van Os, J., Morgan, C., Reininghaus, U., Lewis, C.M., Murray, R.M., Di Forti, M.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Migration history and risk of psychosis: results from the multinational EU-GEI study

  • Tarricone, I.
  • D'Andrea, G.
  • Jongsma, H. E.
  • Tosato, S.
  • Gayer Anderson, C.
  • Stilo, S. A.
  • Suprani, F.
  • Iyegbe, C.
  • Van Der Ven, E.
  • Quattrone, D.
  • Di Forti, M.
  • Velthorst, E.
  • Rossi Menezes, P.
  • Arango, C.
  • Parellada, M.
  • Lasalvia, A.
  • La Cascia, C.
  • Ferraro, L.
  • Bobes, Julio|||0000-0003-2187-4033
The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) Project was funded by grant agreement Health-F2-2010-241909 (Project EU-GEI) from the European Community’s Seventh Framework programme., Tarricone, I., D'Andrea, G., Jongsma, H.E., Tosato, S., Gayer-Anderson, C., Stilo, S.A., Suprani, F., Iyegbe, C., Van Der Ven, E., Quattrone, D., Di Forti, M., Velthorst, E., Rossi Menezes, P., Arango, C., Parellada, M., Lasalvia, A., La Cascia, C., Ferraro, L., Bobes, J., Bernardo, M., Sanjuán, I., Santos, J.L., Arrojo, M., Del-Ben, C.M., Tripoli, G., Llorca, P.-M., De Haan, L., Selten, J.-P., Tortelli, A., Szöke, A., Muratori, R., Rutten, B.P., Van Os, J., Jones, P.B., Kirkbride, J.B., Berardi, D., Murray, R.M., Morgan, C.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Development and validation of predictive model for a diagnosis of first episode psychosis using the multinational eu-gei case-control study and modern statistical learning methods

  • Ajnakina, O.
  • Fadilah, I.
  • Quattrone, D.
  • Bobes, Julio|||0000-0003-2187-4033
OA is funded by the National Institute for Health Research (NIHR) (NIHR Post-Doctoral Fellowship—PDF-2018-11-ST2-020). IF is funded by NIHR Predoctoral Fellowship (NIHR300493). MDF is funded by Clinician Scientist Medical Research Council fellowship (project reference MR/M008436/1). DQ is funded by Post-Doctoral Guarantors of Brain Clinical Fellowship. DS is funded part funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. JBK is supported by National Institute for Health Research, University College London Hospital, Biomedical Research Centre. The EU-GEI Project is funded by the European Community’s Seventh Framework Programme under grant agreement No. HEALTH-F2-2010-241909 (Project EU-GEI). The Brazilian study was funded by the São Paulo Research Foundation under grant number 2012/0417-0., Ajnakina O., Fadilah I., Quattrone D., Arango C., Berardi D., Bernardo M., Bobes J., De Haan L., Del-Ben C.M., Gayer-Anderson C., Stilo S., Jongsma H.E., Lasalvia A., Tosato S., Llorca P.-M., Menezes P.R., Rutten B.P., Santos J.L., Sanjuán J., Selten J.-P., Szöke A., Tarricone I., D'Andrea G., Tortelli A., Velthorst E., Jones P.B., Romero M.A., La Cascia C., Kirkbride J.B., Van Os J., O'Donovan M., Morgan C., Di Forti M., Murray R.M., Hubbard K., Stahl D.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Estimating Exposome Score for Schizophrenia Using Predictive Modeling Approach in Two Independent Samples: The Results From the EUGEI Study

  • Pries, Lotta Katrin
  • Lage-Castellanos, Agustin
  • Delespaul, Philippe
  • Petrovic, S. A.
  • Mirjanic, T.
  • Bobes, Julio|||0000-0003-2187-4033
  • Saiz Martínez, Pilar Alejandra
  • García-Portilla González, María Paz|||0000-0003-3643-1622
  • Genetic Risk and Outcome of Psychosis (GROUP) investigators
The EUGEI project was supported by the grant agreement HEALTH-F2-2010-241909 from the European Community’s Seventh Framework Programme. The authors are grateful to the patients and their families for participating in the project. They also thank all research personnel involved in the GROUP project, in particular J. van Baaren, E. Veermans, G. Driessen, T. Driesen, E. van’t Hag and J. de Nijs. Bart PF Rutten was funded by a VIDI award number 91718336 from the Netherlands Scientific Organisation., Pries, L.-K., Lage-Castellanos, A., Delespaul, P., Kenis, G., Luykx, J.J., Lin, B.D., Richards, A.L., Akdede, B., Binbay, T., Altinyazar, V., Yalinçetin, B., Gümüş-Akay, G., Cihan, B., Soygür, H., Ulaş, H., Cankurtaran, E.Ş., Kaymak, S.U., Mihaljevic, M.M., Petrovic, S.A., Mirjanic, T., Bernardo, M., Cabrera, B., Bobes, J., Saiz, P.A., García-Portilla, M.P., Sanjuan, J., Aguilar, E.J., Santos, J.L., Jiménez-López, E., Arrojo, M., Carracedo, A., López, G., González-Peñas, J., Parellada, M., Maric, N.P., Atbaşoğlu, C., Ucok, A., Alptekin, K., Saka, M.C., Arango, C., O'Donovan, M., Rutten, B.P.F., van Os, J., Guloksuz, S.